

Changing the landscape of cancer



**LLS FUNDED
268**
academic research
grants around the
world in 2016.



2016 annual report

Last year, our Information Resource Center conducted

**6,000 SEARCHES
FOR CLINICAL TRIALS**
for blood cancer patients.



LEUKEMIA &
LYMPHOMA
SOCIETY®

fighting blood cancers

**someday
is today®**

President and Chairman's Message



The fight against cancer is at a unique moment in time. While it is never a good time to get cancer, it is a phenomenal time to be fighting it. The Leukemia & Lymphoma Society (LLS) is on the frontlines.

The combination of new genomic technology, an even deeper understanding of the biology of cancer and the output of new drugs from the pharmaceutical industry make this an extremely exciting time in the field of blood cancer research and treatment.

We saw remarkable progress in treatments for patients with myeloma, chronic lymphocytic leukemia and Hodgkin lymphoma in Fiscal Year 2016, and emerging approaches in immunotherapy and precision medicine continue to show great promise. We entered into new partnerships with biotechnology companies advancing promising new therapies for blood cancer patients, and we played an integral role in supporting Vice President Joe Biden's Cancer Moonshot. LLS is uniquely positioned to lead the charge to find cures and ensure access to treatments for patients with blood cancers.


In addition to our dedicated staff, none of this would be possible without the tens of thousands of volunteers across the country who work every day for patients. It's never been truer – we are a volunteer led, staff driven organization. And we are laser-focused on growth to drive revenue to fuel our mission.

Along with passionate individual and corporate donors, our fundraising campaigns are the driving force moving our mission forward. We are enhancing these iconic programs to capture the imagination of a new generation of donors and participants, and are tapping into the creativity and passion of countless volunteers to elevate awareness of our mission and enhance our ability to stand out in a crowded field of cancer charities and other nonprofits. LLS plays key role in the cancer arena through our ability to convene key stakeholders, including regulatory decision-makers, patients, researchers, top cancer centers, pharmaceutical companies, providers, payors and policy makers. We support breakthrough research and impactful policy initiatives, and provide meaningful patient support and education. LLS is better equipped than ever to make someday today for the 1.2 million people in the United States living with, or in remission from, a blood cancer.

Despite progress we still have much work to do to find cures and help patients access lifesaving treatments. With your continued support we will continue to move closer to cures, changing the landscape of cancer forever.



Louis J. DeGennaro, PhD
President and CEO



James H. Davis, PhD, JD
Chairman of the Board

Fundraising campaigns: The fuel making someday today

Volunteers fuel our mission: As a nonprofit, LLS relies on the generosity of individuals, corporations and foundations.



650,000+

participants
have raised funds
through
Team In Training
marathons,
triathlons, cycling
& hiking events.



860 participants
competed for the
Man & Woman
of the Year title in 2016.



Light The Night® Walk

Families and communities honored blood cancer survivors, as well as those lost to the diseases, by taking part in nearly 200 Light The Night Walks across North America in Fall 2015. Sponsors as well as friends, family and corporate teams raised more than \$61 million for blood cancer research. For the third year, actor and musician Charles Esten volunteered his time as the National Light The Night Walk honorary chair in recognition of the impact LLS research has had on pediatric cancer care.

Team In Training®

Team In Training (TNT), the world's largest and most successful endurance sports training program for charity, is raising the bar on its efforts to create a world without blood cancers. Thousands of "teammates" volunteered for TNT in Fiscal Year 2016 to inspire personal discovery and help turn training into treatments for blood cancer patients. Funds raised through this premier charity sports program help LLS lead the way in finding therapies that are saving lives today. Teammates can choose to run or walk a marathon or half marathon, swim, bike and run a triathlon, embark on a century bike ride (100 miles) or set out on a hiking adventure. They become part of a supportive team and benefit from high-caliber coaching that helps achieve fitness goals. The program raised \$33.7 million in Fiscal Year 2016, and has raised more than \$1.5 billion over the past 28 years.

Student Series™

In Fiscal Year 2016, volunteers in the combined Student Series: Pennies for Patients, Pasta for Pennies presented by Olive Garden, and Hop for Leukemia raised a total of \$26.5 million. Nearly 13 million students in 25,000 schools learned about service, leadership and philanthropy, and saw firsthand how their involvement made a difference in helping save the lives of blood cancer patients.

Man & Woman of the Year

The 2016 Man & Woman of the Year set another campaign record. For 10 weeks, in more than 80 cities across the country, 860 dedicated community leaders with more than 6,200 registered team members volunteered their time and energy to compete locally to win the prestigious national title of LLS's Man & Woman of the Year. Candidates raised \$38 million, surpassing last year's total by more than \$5 million.

Amanda Bush of Texas, daughter-in-law of Jeb Bush, and Jim Chrisman of Colorado, were the leading 2016 fundraisers, with \$489,417 and \$419,399 raised, respectively. Notably, Amanda Bush, who set a new record for the highest amount raised by a candidate, ran in memory of Robin Bush, the daughter of former President George H.W. Bush and First Lady Barbara Bush. Robin was just 3 years old when she died of leukemia in 1953.

This year's All Star Alumni winners were Tam Driscoll of Portland, OR, and Joseph Vicari of Detroit, MI, raising nearly \$400,000 combined.



Man & Woman of the Year National Winners

**Amanda Bush of Texas
and Jim Chrisman
of Colorado**

Leukemia Cup Regatta

The Fiscal Year 2016 Leukemia Cup Regatta campaign grossed nearly \$3.9 million, a 5% increase over the prior fiscal year. More than 11,000 sailors, powerboaters and standup paddlers, and the general public volunteered in Leukemia Cup activities. Sailing legend Gary Jobson, a lymphoma survivor, continued his service as the national chair of the Leukemia Cup Regatta series, which consists of events throughout the United States and Canada. More than \$58 million has been raised through the Leukemia Cup Regatta series since its start 30 years ago at the Pine Harbor Yacht Club in Birmingham, AL (now Birmingham Sailing Club), when the area sailing community decided to hold a race in memory of Stan Wrobel, a local sailor who lost his life to leukemia.

Partnerships

United Food and Commercial Workers Union (UFCW)

The UFCW has been a powerful voice for LLS for 33 years, with its members raising more than \$80 million for LLS in that time span. In Fiscal Year 2016 alone, the UFCW generated nearly \$2 million in the United States, and more than \$2.4 million in Canada, through a variety of fundraising efforts ranging from golf outings and banquets to auctions and dinners. Thousands of UFCW staff and members volunteered in this year's Light The Night Walk, and they contributed more than \$250,000 to that effort. In Canada, the extraordinary one-day "bottle drive" raised more than \$1.6 million.

Burlington

Burlington Stores partnered with LLS's Light The Night Walk campaign for the 14th consecutive year to help support blood cancer research and advance new treatments for cures. The off-price retailer – LLS's largest national partner – encouraged customers to donate to the cause at check-out and raised more than \$3.3 million. That brings Burlington's grand total collection since the partnership's inception to well over \$25 million.

Walgreens

LLS launched an innovative collaboration with Walgreens Specialty Pharmacy to create new approaches to support cancer patients in their communities, provide educational tools and resources for enhanced patient support and implement a pharmacist education and training program. Walgreens has been a longstanding supporter of LLS and will accelerate community engagement and corporate support for the Light The Night Walk.

runDisney

In January 2016 Team In Training and runDisney celebrated our 20th Anniversary at the *Walt Disney World*® Marathon in Orlando, FL. Our partnership over the past 20 years has resulted in more than 28,800 teammates participating and more than \$82.5 million raised at *Walt Disney World*® Marathon Weekend! When we tally the total mission impact at all runDisney events, it is over 34,000 teammates and more than \$98 million raised for LLS.

Bike the West

Since 1997 when we first packed up bikes in cardboard boxes to ship to South Lake Tahoe, more than 24,000 Team In Training cyclists have enjoyed America's Most Beautiful Bike Ride. June 2016 saw Team In Training and Bike the West celebrate our 20th year participating in this event and our fundraising total eclipse \$94 million raised for LLS.



UFCW

UFCW has been a powerful voice for LLS for 33 years, raising more than \$80 million.

Donor Development

Charitable donations fuel every aspect of the LLS mission. With direct gifts that totaled \$35.6 million, donors enthusiastically donated resources for research and patient programs. Highlights included a \$1 million gift from Drenda Vijuk in memory of her husband, Joe, a chronic myeloid leukemia patient. Also, the Harry T. Mangurian, Jr. Foundation made a second multi-million dollar commitment to acute myeloid leukemia (AML) research, ensuring its progression to the clinical trial phase. Other donors who directly supported LLS's Therapy Acceleration Program® (TAP), a strategic initiative to invest directly in biotechnology companies, were gratified by significantly increased survival data from a Phase 3 trial by TAP partner Celator Pharmaceuticals.


LLS gratefully acknowledges all donors who fund the mission and proudly lists gifts of \$10,000 or more within the pages of this report. We also honor the memories of thoughtful people who use lifetime assets to make their largest gifts through bequests or beneficiary designations in retirement plans. Nearly \$8 million was received in this manner during the year. Giving also includes our Blood Cancer Awareness Month activities and online fundraising.

Blood Cancer Awareness Month

LLS launched a comprehensive marketing and communications campaign in September 2015 for Blood Cancer Awareness Month. The effort involved printed materials, website pages, digital and social media, email support and public relations across national and local markets, and was further boosted by a "Turn it Red" campaign wherein more than 40 landmarks across the nation and internationally turned their lights red throughout the month.

Online Fundraising

Online fundraising continues to increase in importance to LLS, and is driven largely by our digital marketing efforts. Specifically, we take advantage of sophisticated digital targeting capabilities to recruit participants to join our fundraising campaigns, support them in their own fundraising efforts, keep them engaged and informed post-event, and encourage their ongoing participation. We also use these channels to drive direct donations, particularly during seasonally driven opportunities such as Blood Cancer Awareness Month (September), Giving Tuesday (first Tuesday post-Thanksgiving) and December when all charitable giving peaks.




TURN IT RED

The 35 W Bridge in
Minneapolis, MN.
Photo courtesy of
KaiserClix.


Research that is changing the landscape of cancer

The LLS research agenda is focused on finding cures and driving research in areas of unmet medical need.



LLS HAS INVESTED MORE THAN **\$1 BILLION**

in research to advance cancer treatments and cures.



Research Spending

LLS's total research funding for Fiscal Year 2016 was \$49.3 million across academic grants and the Therapy Acceleration Program (TAP). The majority of our research commitments are multi-year and reflected below is the fiscal spending.

Academic Grants

LLS's academic research grant funding in Fiscal Year 2016 was \$40.3 million, with 268 grants funded during the year. LLS announced a commitment to invest \$28.6 million in new multi-year grants, with the first year of those grants supported by the Fiscal Year 2016 budget for \$11.49 million. In addition to seeking cures and better treatments for patients, cancer researchers play critical roles with LLS, volunteering their time on boards to review research applications for grants and serving as panelists for our research symposia and educational programs.

Therapy Acceleration Program

LLS supported 22 projects through its Therapy Acceleration Program (TAP), a strategic initiative through which we build business alliances and collaborations with biotechnology companies and academic researchers to speed the development of new therapies and diagnostics. In Fiscal Year 2016 \$9.3 million was invested in new and on-going TAP commitments. Several of our TAP partners celebrated significant milestones in Fiscal Year 2016.

Stemline Therapeutics

TAP partner Stemline Therapeutics reported promising results in 2016 for a therapy to treat a rare blood cancer, blastic plasmacytoid dendritic cell neoplasm, which has no approved standard of care. Stemline reported during the American Society of Clinical Oncology meeting that 89% of patients in a clinical trial had an overall response to its drug, SL-401. The drug, which targets the CD123 protein present on a wide range of blood cancers, is also being tested in AML and multiple myeloma (MM).

Celator Pharmaceuticals

LLS's TAP partner Celator Pharmaceuticals (recently acquired by Jazz Pharmaceuticals) announced positive data in Fiscal Year 2016 for its investigational therapy CPX-351 (Vyxeos™) from an LLS-supported Phase 3 clinical trial. Celator's innovative formulation of two standard chemotherapy drugs performed significantly better than the standard therapy, including a statistically significant improvement in overall survival in the clinical trial for newly diagnosed patients, age 60-75, with high-risk (secondary) AML. Based on the outcome of the trial, a new drug application is anticipated some time in Fiscal Year 2017. If approved by the FDA, this would mark the first time that LLS's direct investment in a biotechnology company has enabled a newly approved therapy to reach thousands of patients, a significant achievement for LLS's venture philanthropy initiative.



Jerry Adams, PhD

Walter & Eliza Hall
Institute of Medical
Research, Melbourne,
Australia, leads an LLS
Specialized Center of
Research whose work
contributed to approval
of venetoclax for
patients with a high-
risk subset of chronic
lymphocytic leukemia
(CLL).



Beat AML

Drs. John Byrd, The Ohio State University; Ross Levine, Memorial Sloan Kettering Cancer Center; and Brian Druker, Oregon Health & Science University Knight Cancer Institute, all helping LLS lead the Beat AML initiative.

Valor Biotherapeutics

In Fiscal Year 2016 LLS's TAP partner Valor Biotherapeutics initiated its first-in-human, Phase 1 clinical study of IGN002, a novel investigational treatment for non-Hodgkin lymphoma (NHL). IGN002 is a therapy combining an antibody and a cytotoxic agent to target the CD20 protein in lymphoma patients. LLS has been supporting Valor's pre-clinical development and manufacturing of the drug over the past two years.

Kiadis Pharma

LLS initiated a new partnership with Kiadis Pharma through an equity investment into the development of ATIR101™, an innovative T-cell immunotherapy for blood cancers. This partnership was further strengthened by a second equity investment in July. This TAP investment supports Kiadis' second ongoing Phase 2 trial in leukemia patients, and will be continued into a Phase 3 pivotal study. ATIR101 is a therapy, for adult AML and acute lymphoblastic leukemia (ALL) patients undergoing a stem cell transplantation procedure using donor cells from a half-matched donor who is related to the patient. Stem cell transplantation is one of the most effective curative treatments for blood cancer patients, but it comes with great risk of life-threatening infection and graft versus host disease (GVHD). Kiadis Pharma's ATIR101™ shows promise in fighting these infections by boosting the patient's immune system while also reducing GVHD.

Beat AML

More than 20,000 patients a year are diagnosed with AML and 10,000 will die annually. LLS continued to lead the offensive against AML in Fiscal Year 2016. We convened an unprecedented collaboration of academic researchers, pharmaceutical companies, a genomic provider, and the Food & Drug Administration to lay the groundwork for a multi-site, multi-treatment arm AML Master Trial. We are set to begin enrolling patients in Fiscal Year 2017. The groundbreaking Beat AML Master Trial will employ advanced genomic technology to enable a precision medicine approach. The goal is to rapidly identify patients' genetic mutations so the patient can be directed to the appropriate trial testing a novel targeted therapy most likely to be effective for their genetic profile. The trial is expected to improve outcomes for AML patients as there has been no change in the standard of care for this patient population in 40 years.

American Society of Hematology

The 57th American Society of Hematology (ASH) Annual Meeting brought tens of thousands of researchers to Orlando to present data from thousands of clinical trials, with encouraging results for cutting-edge approaches to targeted therapy and immunotherapy. Chimeric antigen receptor therapy (CAR-T), one of a number of methods under development to harness the body's immune system to kill cancer cells, continued to garner attention.

LLS-funded researchers were well-represented at the meeting. Researchers from University of Pennsylvania, where LLS has been supporting a CAR-T program for two decades, presented encouraging results in various studies for patients with lymphoma, ALL and CLL.

CLL afflicts approximately 19,000 new patients per year in the United States. Over the past three years, LLS investment in new research and therapies for CLL has dramatically paid off. Our investment helped advance new therapies approved by the FDA in 2016 for CLL treatment, including ibrutinib and venetoclax. In particular, in 2016, an LLS Specialized Center of Research (SCOR) team, headed by Thomas Kipps, MD, PhD, at University of California San Diego presented data at the ASH meeting showing ibrutinib was superior to a standard chemotherapy in treating CLL patients. These findings contributed to the FDA approval of ibrutinib as a first-line treatment for newly diagnosed CLL patients in place of chemotherapy. In addition, The Ohio State University blood cancer scientist John Byrd, MD, whose work LLS has supported for almost two decades, presented several new CLL studies at the ASH meeting. His LLS-supported work led to the original approval of ibrutinib for CLL in 2014. At the ASH meeting he presented data on another investigational drug that targets BTK, the same protein that is targeted by ibrutinib, and appears to be even more effective.

Another study by an LLS SCOR team at the Walter & Eliza Hall Institute of Medical Research (WEHI) in Australia showed that 92% of the study's relapsed CLL patients responded to venetoclax, which targets the BCL-2 protein in cancer cells. BCL-2 controls the life or death of a cell. Venetoclax was FDA approved later in Fiscal Year 2016 for a subset of patients with a high-risk form of CLL. Since 2002, LLS has supported more than \$15 million in research leading to the development of this drug through its collaborative SCOR program.



ASH Symposium

**Panelists for LLS's
Pre-ASH Satellite
Symposium:
"Molecularly
Targeted Therapies
for Hematologic
Malignancies."**

LLS's Satellite Symposium

LLS sponsored a satellite symposium in Orlando in advance of the ASH meeting titled "Molecularly Targeted Therapies for Hematologic Malignancies."

Five prominent blood cancer experts volunteered their time as panelists, highlighting efforts to develop precisely targeted therapies that go after the tumor cells while sparing the healthy cells. More than 600 attendees learned the latest advances in AML, T-cell acute lymphoblastic leukemia (T-ALL), CLL and MM.

A Special Roundtable Discussion

LLS brought together a world-renowned panel of thought leaders from research, clinical practice, policymaking, the pharmaceutical industry and patient advocacy to discuss the latest advances in blood cancer research and treatment, cost of care and patient advocacy and policy. The signature event, titled "Blood Cancers: Standards of Care, Gateways to Cancer Cures," was held in New York City and addressed collaboration, access to treatments, venture philanthropy, precision medicine and AML, targeted therapies and the promise of immunotherapy.

Supporting the Moonshot

LLS is actively supporting Vice President Biden's Cancer Moonshot initiative in an effort to accelerate cancer cures.

Dr. DeGennaro was one of many leaders representing the cancer community in Biden's daylong National Cancer Moonshot Summit at Howard University in Washington, D.C., on June 29. The group discussed new ideas and collaborations, and Dr. DeGennaro led a breakout session, "Advancing Research Discoveries and Catalyzing Scientific Breakthroughs."

Simultaneously, LLS hosted the "LLS Cancer Moonshot Town Hall," a national webcast to more than 900 participants, to show how the organization's work is aligned with that of the Moonshot initiative.

Dr. DeGennaro also joined an expert panel at the annual Milken Institute Global Conference, "Promise of the Cancer Moonshot," to share LLS's perspective about what needs to be done to move this effort forward.



LLS Roundtable

Panelists at LLS Roundtable: "Blood Cancers: Standards of Care, Gateways to Cancer Cures."

Last year alone
LLS invested

\$49.3
MILLION



IN CUTTING-EDGE
RESEARCH.

Research Advances Highlighted in Media Tour

The American Society of Clinical Oncology (ASCO) meeting took place in Chicago June 3-7. As the world's largest cancer conference, it affords an opportunity for researchers from around the world to share their latest data from cancer clinical trials. To kick off the meeting, LLS President and CEO Louis J. DeGennaro was joined by Gail Roboz, MD, Professor of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, for a satellite media tour in New York City, to address the latest research news coming out of the annual ASCO meeting. They participated in interviews with 25 TV and radio stations across the country. Dr. DeGennaro discussed LLS's role in advancing new and better treatments and ensuring access, and Dr. Roboz shared her experience as an expert in AML.

Patient and Professional Education

In 2016, LLS's Patient Access department delivered 10 live disease-focused webinars nationally, with more than 3,200 participants. Our patient and professional videos and virtual lectures have been downloaded more than 20,000 times, and more than 600,000 disease and support booklets were distributed.

Additionally, LLS chapters hosted 168 local community-based education programs for patients, caregivers and healthcare professionals, and five local interactive grand rounds for physicians. A symposium focused on clinical trials and CAR-T therapy was held at the annual Oncology Nursing Society conference with more than 600 attendees.



Media Tour

LLS CEO and President Louis J. DeGennaro joined researcher Gail Roboz, MD, of Weill Cornell Medicine/NY Presbyterian Hospital, for a satellite media tour to discuss cancer advances from the American Society of Clinical Oncology annual meeting.

Working to ensure access to care for all blood cancer patients

The goal of The Leukemia & Lymphoma Society is to reach patients soon after diagnosis to provide support, disease and treatment information, and access to quality care. LLS continues to be a leader in the delivery of blood cancer education and in enhancing patient access to treatments.



\$40+ MILLION
provided in co-pay assistance.

Information Resource Center

Callers to LLS's Information Resource Center (IRC) speak one-on-one with master's degree level healthcare professionals who help them deal with the challenges of a blood cancer diagnosis. Information specialists offer accurate, current disease treatment and support information, and they guide patients through the psychosocial and financial challenges of blood cancer treatment and survivorship. More than 26,000 inquiries were handled by the IRC in Fiscal Year 2016. The IRC's clinical trial navigator assisted 167 patients with complex clinical trial searches, and 49% enrolled in a trial. Information specialists can be reached at (800) 955-4572 between 9 a.m. and 9 p.m. ET Monday through Friday.

Patti Robinson Kaufmann First Connection Program

The *Patti Robinson Kaufmann First Connection Program* helps newly diagnosed patients cope with their disease by matching them with trained volunteers who have also been touched firsthand by a blood cancer. The peer-to-peer program successfully matched more than 700 patients with volunteers in Fiscal Year 2016.

Co-Pay Assistance

LLS's Co-Pay Assistance Program helps eligible blood cancer patients pay for their prescription drug co-pays and health insurance premiums. LLS provided more than \$40 million to patients in Fiscal Year 2016 through this program.

LLS Community Launch

LLS's mission includes searching for the best outcomes for patients and in that regard has committed to building a national database of all blood cancer patients to compare and contrast treatment experiences. Toward that endeavor, the first phase of this project – The LLS Community – was launched in Fiscal Year 2016. This online site has the familiar look and feel of modern social media sites, but offers an extended conversation and a sense of community. Visitors set up a free account and those recently diagnosed or living with a blood cancer fill out a profile about their diagnosis and treatment. Caregivers as well as supporters are invited to join. In return, all are provided disease-specific information, news and supportive discussion groups as well as inclusion in periodic research surveys. More than 2,500 have joined since the launch in 2016.

Laws to Make Oral Drugs More Affordable

The governors of both Alaska and Pennsylvania signed oral parity laws in 2016, bringing the number of supporting states to 42 plus the District of Columbia. The laws extend a critically important financial protection to thousands of patients living with cancer by ensuring that medications taken orally (self-administered) will receive equitable healthcare coverage to those who receive treatment via infusion or injection in a clinical setting. LLS has been a key player in efforts to pass oral parity laws, leading the coalition in Pennsylvania for the past seven years, growing it to more than 20 patient organizations, healthcare provider associations and the most prominent academic health centers in the state. Volunteer patient advocates played critical roles in helping to get these laws passed, testifying before legislators and participating in letter-writing campaigns.



Blood Cancer Conferences

LLS conducted 10 regional blood cancer conferences, free educational programs for patients, caregivers and healthcare professionals, with nearly 3,000 patients and caregivers in attendance. These conferences provide opportunities to learn more about treatment options, emerging therapies, management of survivorship issues and LLS resources. The conferences would not be possible without the dedication of countless volunteers who serve as speakers, facilitators, guides and committee members, and who perform administrative tasks – everything from registering guests to distributing pamphlets.

Voice for all blood cancer patients

LLS is the voice of all blood cancer patients and is dedicated to removing barriers to care.



100,000+



state-based
VOLUNTEER
ADVOCACY TEAMS
across the country.



Bringing the Patient Voice into Drug Development

LLS brought a delegation of 15 AML survivors, seven caregivers and other LLS leaders to Washington, D.C., in April to share personal experiences with the FDA and discuss plans for a research study to learn what patients and caregivers are looking for in new treatments. The survivors and caregivers engaged in a roundtable dialogue with Richard Pazdur, MD, FDA director of the Office of Oncology Drug Products, and 20 of his staff and colleagues.

LLS is collaborating with The Johns Hopkins School of Public Health to develop an innovative research study, “Quantifying Patient and Caregiver Preferences for the Treatment of AML,” designed to understand patient experiences and expectations, their AML-related worries, and their preferences for the benefits and risks of treatment. A pilot study was conducted in Fiscal Year 2016 and will be expanded in Fiscal Year 2017 to between 100 and 200 people. Ultimately, LLS’s hope is that the results will be used to help ensure that both the FDA and drug manufacturers better understand patients’ and caregivers’ perspectives and include their preferences in the drug development process.

LLS Volunteer Engagement Initiative

It has never been truer, or more necessary, for LLS to fulfill its vision as a volunteer led, staff driven organization. Throughout 2016, we have stepped up efforts to empower passionate leaders to help drive recruitment, engagement and growth of all of our campaigns. Volunteers also play critical roles in our patient access and policy initiatives.

They are extraordinary individuals, companies, clubs and organizations, all dedicated to helping LLS advance its mission. Our volunteers are at the heart of everything we do at LLS. They give their time and talent to make significant differences in the lives of patients and their families in so many ways. Some have achieved remarkable fundraising goals. Others dedicate their services to providing support and expertise for the patients we serve. Some have contributed by helping to create a national program or by helping to elevate LLS’s public profile.



FDA Delegation

AML survivors joined LLS staff at FDA meeting.

Volunteers

LLS Volunteer Engagement Initiative



LLS implemented the 2016
**NATIONAL RECOGNITION
& AWARDS PROGRAM**

Highlighting the significant contributions of the volunteers who impact our organization and patients.

Throughout 2016 we developed and implemented robust volunteer engagement strategies across our mission and campaign programs to strengthen our efforts to reach and help more patients and support more revenue channels.

- As a critical example, we created a new Patient Access Volunteer Development Program designed to increase our ability to reach and support patients and caregivers soon after diagnosis, and to broaden volunteer engagement in the work of patient access and the organization as a whole. With this program, it is our goal to generate heightened community awareness of LLS and to connect more patients and caregivers with LLS resources so that anyone facing a blood cancer has access to high quality care and can be strengthened by the experiences of others.
- Our volunteer advocates played key roles in our efforts to advance laws and policies to ensure patients have greater access to therapies by testifying in person before government officials and sharing their stories in person, through social media, and letter-writing campaigns.

Importantly, we implemented a National Recognition and Awards program in 2016 to highlight the significant contributions of the volunteers who impact our organization and the patients we help in so many ways every day. Throughout the year, we took opportunities to recognize these invaluable volunteers and on the following pages you will find each volunteer who was recognized in 2016.

Bryce Harper

LLS hit a homerun when Washington Nationals outfielder Bryce Harper announced LLS will be a beneficiary of his limited edition, custom-designed baseball caps. Harper has supported LLS through Harper's Heroes, a program for kids battling blood cancers, since 2013.

L to R: Bryce Harper; Mason Mazzuca, 5-year-old ALL patient and LLS Honored Hero; Mike Rizzo, general manager and President of Baseball Operations for the Nationals

Craig Sager

A week after receiving the Jimmy V Perseverance ESPY Award, NBA Sideline Reporter Craig Sager delivered an inspirational keynote speech about the importance of faith and hope at LLS's Atlanta Blood Cancer Conference. Sager was diagnosed with AML in 2014.

L to R: Craig Sager, Stacy Sager, Piper Medcalf, Dr. Lou DeGennaro

2016 National Recognition & Awards Program

Recognition of the extraordinary involvement of individuals, companies, corporations and organizations in their support of LLS and its mission. Those honored give of their time, talent and treasure and have made a significant difference in the lives of so many. To find out more about our awards program, please go to <https://www.lls.org/national-awards-nomination>.

Congratulations to all the 2016 awardees!

2016 National Recognition & Awards Recipients

Return of the Child Award

Researcher or clinician who has focused their entire career to helping find cures and save lives.

John Byrd, MD
Central Ohio Chapter

Tree of Life Award

Individual, member of medical or scientific community, who has implemented a program or service to support blood cancer patients and their families.

Karen Albritton, MD
North Texas Chapter

Spiral of Life Award

Individual who contributes personal and professional talents to advance an LLS national campaign or program.

James H. Davis, PhD, JD
National Capital Area Chapter

Jim McKinnis
North Texas Chapter

Vision for Life Award

Individual, corporation, or organization who, by thinking outside of the box, helped to create a new national campaign or program.

Bernard and Ethel Garil
Palm Beach Area Chapter

Duncan Glew
Eastern Pennsylvania Chapter

Dr. John J. Kenny Award

Member of medical community, a social worker, or a caregiver who supports patient services.

Nancy Boyle, MSW, LCSW, OSW-C
Oregon SW Washington Idaho Montana Chapter

David William Hirsch
North Carolina Chapter

Karen King
North Texas Chapter

Dr. William Dameshek Award

Public figure who has helped focus national attention to LLS.

Kevin Alston
Massachusetts Chapter

Eric Berry
Mid-America Chapter

Jon Bonnell
North Texas Chapter

Bryce Harper
National Capital Area Chapter

Craig Sager
Georgia Chapter

Rabbi David Wolpe
California Southland Chapter

Dr. Kenneth B. McCredie Award

Individual or corporation who has supported LLS for at least five (5) years and helped raise more than \$1 million.

Lawrence J. "Doc" Cohen
Texas Gulf Coast Chapter

Elbit Systems of America
North Texas Chapter

EY
New York City Chapter

Gilles Legault
LLS Canada Chapter

The Manos Family
CTWHV Chapter

The Newman Family
National Capital Area Chapter

Partners For A Cure
Greater Sacramento Area Chapter

Sempre Energy
California Southland Chapter

Stater Bros. Markets
Orange County Inland Empire Chapter

Partners Against Blood Cancer Award

Ruby (40+ years of partnership)

Robert "Spider" Cantley
Greater Bay Area Chapter

Diamond (30+ years of partnership)

Birmingham Sailing Club
Alabama/Gulf Coast Chapter

Houston Police Department
Bicycle Relay Team
Texas Gulf Coast Chapter

LeRoy Smigel
Central Pennsylvania Chapter

Summer Solstice Committee
Central Pennsylvania Chapter

Platinum (20+ years of partnership)

Dallas Marathon
North Texas Chapter

Links Fore Leukemia
North Texas Chapter

The Niello Company
Greater Sacramento Area Chapter

Gold: (15+ years of partnership)

Burbank High School
California Southland Chapter

Compass Oncology
Oregon SW Washington Idaho
Montana Chapters

Patterson Road Elementary
School
California Southland Chapter

Marian Riestenberg
Tri-State Southern Ohio Chapter

Silver (10+ years of partnership)

Christbridge Academy
California Southland Chapter

Dallas Athletes Racing
North Texas Chapter

Dana Middle School
California Southland Chapter

GE Aviation
Tri-State Southern Ohio Chapter

Geico
North Texas Chapter

2016 National Media Awards Recipients

Manatt Phelps & Phillips LLP
California Southland Chapter

PwC
Silicon Valley & Monterey Bay
Area Chapter

SanDisk
Silicon Valley & Monterey Bay
Area Chapter

Silicon Valley Bank
Silicon Valley & Monterey Bay
Area Chapter

South Pasadena Middle School
California Southland Chapter

Bronze: (5+ years of partnership)

A.C.E. Family Foundation
Long Island Chapter

Alaska Airlines
Washington & Alaska Chapter

BMC
North Texas Chapter

HFF
North Texas Chapter

Honored Hero Run
North Texas Chapter

Marge & Charles Schott
Foundation
Tri-State Southern Ohio Chapter

Playtri
North Texas Chapter

Round Meadow Elementary
School
California Southland Chapter

Thompson & Knight
North Texas Chapter

President's Award

Recognizes a volunteer whose personal commitment and dedication inspires and motivates others to support our mission and help make Someday Today.

Christine Attia
Greater Bay Area Chapter

Board Citation Award

Corporation or organization whose ongoing commitment and dedication is worthy of national recognition.

American Electric Power
Central Ohio Chapter

Pat Harwood
Minnesota Chapter

Huntington National Bank
Central Ohio Chapter

KeyBank of Oregon
Oregon SW Washington Idaho
Montana Chapter

Richard Loomis
SVP and CMO,
Disney Channels Worldwide
California Southland Chapter

William Mason High School
Tri-State Southern Ohio Chapter

Chairman's Advocacy Award

Volunteer, advocate or legislator recognized for support of LLS's advocacy efforts.

Virginia Garner
California Southland Chapter

Senator Bill Ketron
Tennessee Chapter

BGen (ret) Steven A. Roser
North Texas Chapter

R. Keith Traster
North Texas Chapter

Chairman's Citation Award

Individual whose dedication to LLS is worthy of national recognition.

Marie Achatz
Long Island Chapter

Evelyn Bata, MD
National Capital Area

Jim Filiatrault, TCF Bank
Minnesota Chapter

Paul Fox
Illinois Chapter

Kerry Garnett
San Diego / Hawaii Chapter

Neil & Emily Kishter
National Capital Area Chapter

Ravindra Majeti, MD, PhD
Silicon Valley & Monterey Bay
Area Chapter

Lois Markovich
Greater Bay Area Chapter

Kyle Mostransky
Long Island Chapter

Todd Oakes
Minnesota Chapter

William Patterson
Greater Bay Area Chapter

Lilian Pena
Greater Bay Area Chapter

Susan Reid
Virginia Chapter

PJ Rizvi
Palm Beach Area Chapter

Ruth Robinson
North Texas Chapter

Brint Ryan
North Texas Chapter

Melinda Spaulding
Texas Gulf Coast Chapter

Gary Thompson
South Central Texas Chapter

Amanda Tiede
National Capital Area Chapter

Nitasha Wallace (Premier Banks)
Minnesota Chapter

Daniel Weng
Central Ohio Chapter

Recipients have a record of excellence in promotional support/fundraising, as well as educating and informing the public of the LLS organization and its mission.

Digital

Kevin Mumphrey and
Rene Michele
MVP Productions
Mississippi/Louisiana Chapter

Print

Albany Business Review
Upstate New York &
Vermont Chapter

APG Media of Chesapeake LLC
Maryland Chapter

Jennifer Bertetto
TRIB Total Media
Western Pennsylvania &
West Virginia Chapter

Boston Magazine
Massachusetts Chapter

Marcus Fuller
St. Paul Pioneer Press
Minnesota Chapter

GFR Media/El Nuevo Dia
Southern Florida & Puerto Rico
Chapter

Dustin Holt
APG Media of Chesapeake LLC
Maryland Chapter

Leah Palone
Boston Magazine
Massachusetts Chapter

San Diego Union Tribune
San Diego & Hawaii Chapter

St. Paul Pioneer Press
Minnesota Chapter

TRIB Total Media
Western Pennsylvania & West
Virginia Chapter

Radio

Kristi Carson
Emmis Communication
Gateway Chapter

Reggie Dee
X102.3 FM
Palm Beach Area Chapter

Emmis Communication
Gateway Chapter

Micki Gamez
iHeart Radio
South Central Texas Chapter

iHeart Radio
Rhode Island Chapter

iHeart Radio
South Central Texas Chapter

Rhonda Lapham
iHeart Radio
Rhode Island Chapter

Dr. Daliah Wachs
Southern Nevada

X102.3 FM
Palm Beach Area Chapter

Television

ABC7
Greater Bay Area Chapter

CW6
San Diego & Hawaii Chapter

Doug Dunbar
CBS11
North Texas Chapter

Lynda Martin
CW6
San Diego & Hawaii Chapter

Elex Michaelson
KABC-7
California Southland Chapter

KABC-7
California Southland Chapter

Nina Moini
WCCO-TV/CBS
Minnesota Chapter

Christine Pullara
WXIA-TV
Georgia Chapter

Melinda Spaulding
KRIV-Fox 26
Texas Gulf Coast Chapter

Jill Wagner
California Southland Chapter

Melissa Wilson
KRIV-TV 26
Texas Gulf Coast Chapter

WLKY
Kentucky & Southern
Indiana Chapter

Shannon Wolfson
KXAN
South Central Texas Chapter

WCCO-TV/CBS
Minnesota Chapter

WXIA-TV Channel 11
Georgia Chapter

Research Grants

Specialized Center of Research

The Specialized Center of Research Program funds multi-disciplinary research by teams of leading-edge academic investigators that hastens the discovery and development of better treatments for leukemia, lymphoma and myeloma patients. A center is comprised of at least three independent research programs that are integrated and supported by scientific core laboratories.

Jerry Adams, PhD 2013
Walter & Eliza Hall Institute of Medical Research

Jon Aster, MD 2013
Brigham and Women's Hospital

John Byrd, MD 2011¹
The Ohio State University

William Carroll, MD 2014
New York University School of Medicine

Irene Ghobrial, MD 2014
Dana-Farber Cancer Institute

Helen Heslop, MD 2014
Baylor College of Medicine

Carl June, MD 2013²
University of Pennsylvania

Thomas Kipps, MD, PhD 2014
University of California, San Diego

Jonathan Licht, MD 2013
University of Florida

Ari Melnick, MD 2016*
Weill Cornell Medical College

David Weinstock, MD 2016*
Dana-Farber Cancer Institute

Career Development Program (Scholars and Clinical Scholars)

The Career Development Program provides stipends to investigators of exceptional promise in the early stages of their careers, helping them devote their careers to research in leukemia, lymphoma or myeloma.

Omar Abdel-Wahab, MD 2017*
Memorial Sloan Kettering Cancer Center

Gregory Abel, MD 2013
Dana-Farber Cancer Institute

K Mark Ansel, PhD 2013
University of California, San Francisco

Saro Armenian, DO, MPH 2017*
Beckman Research Institute of City of Hope

Uttiya Basu, PhD 2016
Columbia University Medical Center

Julie Blander, PhD 2015
Icahn School of Medicine at Mount Sinai

Patrick Brown, MD 2012³
The Johns Hopkins University School of Medicine

Jan Burger, MD, PhD 2014
The University of Texas MD Anderson Cancer Center

Fernando Camargo, PhD 2016
Boston Children's Hospital

Iain Cheeseman, PhD 2013
Whitehead Institute for Biomedical Research

Jerry Chipuk, PhD 2017*
Icahn School of Medicine at Mount Sinai

Dipanjana Chowdhury, PhD 2015
Dana-Farber Cancer Institute

Tomasz Cierpicki, PhD 2017*
University of Michigan

Christopher Cogle, MD 2013
University of Florida

Yali Dou, PhD 2013
University of Michigan

Benjamin Ebert, MD, PhD 2013
Brigham and Women's Hospital

Thomas Fazio, PhD 2015
University of Massachusetts Medical School

Benjamin Garcia, PhD 2016
Perelman School of Medicine at the University of Pennsylvania

Ramiro Garzon, MD 2016
The Ohio State University

Irene Ghobrial, MD 2017*
Dana-Farber Cancer Institute

Andrei Goga, MD, PhD 2013
University of California, San Francisco

Jolanta Grembecka, PhD 2014⁴
University of Michigan

David Guertin, PhD 2016
University of Massachusetts Medical School

Katharine Hsu, MD, PhD 2017*
Memorial Sloan Kettering Cancer Center

Morgan Huse, PhD 2015
Memorial Sloan Kettering Cancer Center

John Koreth, MD, PhD 2014⁵
Dana-Farber Cancer Institute

Ross Levine, MD 2013⁶
Memorial Sloan Kettering Cancer Center

Ming Li, PhD 2015
Memorial Sloan Kettering Cancer Center

Ivan Maillard, MD, PhD 2014
University of Michigan

Ravindra Majeti, MD, PhD 2016
Leland Stanford Junior University

Constantine Mitsiades, MD, PhD 2017*
Dana-Farber Cancer Institute

Golam Mohi, PhD 2014
SUNY Upstate Medical Center

Trista North, PhD 2017*
Beth Israel Deaconess Medical Center

Ryoma Ohi, PhD 2014
Vanderbilt University Medical Center

Sophie Paczesny, MD, PhD 2015
Indiana University

Emmanuelle Passegué, PhD 2013
University of California, San Francisco

Cathie Pfleger, PhD 2013
Icahn School of Medicine at Mount Sinai

Talya Salz, PhD 2014
Memorial Sloan Kettering Cancer Center

Joseph Scandura, MD, PhD 2014
Weill Cornell Medical College

Tait Shanafelt, MD 2013
Mayo Clinic

Xiaobing Shi, PhD 2017*
The University of Texas MD Anderson Cancer Center

Merav Socolovsky, MD, PhD 2013
University of Massachusetts Medical School

Daniel Starczynowski, PhD 2016
Cincinnati Children's Hospital Medical Center

Kimberly Stegmaier, MD 2014
Dana-Farber Cancer Institute

Ulrich Steidl, MD, PhD 2015
Albert Einstein College of Medicine, Inc.

Enrico Tiacchi, MD 2014
University of Perugia

Raoul Tibes, MD, PhD 2015
Mayo Clinic Arizona

Wei Tong, PhD 2014⁷
The Children's Hospital of Philadelphia

David Traver, PhD 2013
University of California, San Diego

Christopher Vakoc, MD, PhD 2016
Cold Spring Harbor Laboratory

Amit Verma, MD 2013
Albert Einstein College of Medicine, Inc.

Loren Walensky, MD, PhD 2015
Dana-Farber Cancer Institute

Matthew Walter, MD 2014
Washington University School of Medicine in St. Louis

Roland Walter, MD, PhD, MS 2015
Fred Hutchinson Cancer Research Center

Hengbin Wang, PhD 2013
The University of Alabama at Birmingham

Wenyi Wei, PhD 2014
Beth Israel Deaconess Medical Center

David Weinstock, MD 2014⁸
Dana-Farber Cancer Institute

Hans-Guido Wendel, MD 2015
Memorial Sloan Kettering Cancer Center

Johnathan Whetstone, PhD 2015
Massachusetts General Hospital

Catherine Wu, MD 2015
Dana-Farber Cancer Institute

Xiaochun Yu, MD, PhD 2015
Beckman Research Institute of City of Hope

Shan Zha, MD, PhD 2014
Columbia University Medical Center

Chengcheng Zhang, PhD 2014
UT Southwestern Medical Center

Jing Zhang, PhD 2014⁹
University of Wisconsin System

Xiaolan Zhao, PhD 2014
Memorial Sloan Kettering Cancer Center

Elina Zuniga, PhD 2013
University of California, San Diego

¹ Dr. John Byrd is funded in part by Gerald Kafka & Rita Cavanaugh, Dough Baughman and Madeline & Stephen Anbinder.

² Dr. Carl June is funded in part by Marc & Shari Weissbach.

Dr. Stephan Grupp is funded in part by HM Insurance Group.

Dr. David Porter is funded in part by Rita Cavanaugh & Gerald Kafka.

³ Dr. Patrick Brown is funded in part by Thomas Moore.

⁴ Dr. Jolanta Grembecka is funded in part by Jennifer & Jeffrey Butler.

⁵ Dr. John Koreth is fully funded by an anonymous donor.

⁶ Dr. Ross Levine is fully funded by The Norcross Foundation, Inc.

⁷ Dr. Wei Tong is funded in part by the VWR Charitable Foundation and The Charter Foundation.

⁸ Dr. David Weinstock is funded in part by Zachary Fischer.

⁹ Dr. Jing Zhang is funded in part by the Greater Milwaukee Foundation.

Dr. Chen Fang is funded in part by the Melryder Foundation.

Dr. H. Leighton Grimes is funded in part by The Marge & Charles J. Schott Foundation.

* Newly awarded or renewed grants in Fiscal Year 2017

**Career Development Program
(Special Fellows, Clinical
Special Fellows and Fellows)**

Spencer Alford, PhD 2015
Leland Stanford Junior University

Burton Barnett, PhD 2015
University of California,
San Diego

Cora Bergantinos, PhD 2015
Columbia University
Medical Center

Shruti Bhatt, PhD 2017*
Dana-Farber Cancer Institute

Nicholas Brown, PhD 2016
St. Jude Children's Research
Hospital

Sheng Cai, MD, PhD 2017*
Memorial Sloan Kettering
Cancer Center

Marcella Cesana, PhD 2015
Boston Children's Hospital

Hye Ji Cha, PhD 2017*
Boston Children's Hospital

Huan Chen, PhD 2017*
Boston Children's Hospital

Michael Chu, MD 2015
Leland Stanford Junior University

Ahmet Coskun, PhD 2016
California Institute of Technology

Madzia Crossley, PhD 2017*
Leland Stanford Junior University

Ana Carolina da Silva Almeida,
PhD 2017*
Columbia University
Medical Center

Sarah Deng, PhD 2017*
New York University
Medical Center

Dan Dominissini, PhD 2016
The University of Chicago

Zhixun Dou, PhD 2015
University of Pennsylvania

Jonathan Esensten, MD,
PhD 2017*¹⁰
University of California,
San Francisco

Eva Fast, PhD 2015
President & Fellows
of Harvard College

Craig Forester, MD 2016
University of California,
San Francisco

Jacqueline Garcia, MD 2015
Dana-Farber Cancer Institute

Charles Gawad, MD 2014¹¹
Leland Stanford Junior University

Stephanie Grainger, PhD 2015
University of California,
San Diego

Sarah Hainer, PhD 2017*
University of Massachusetts
Medical School

Andrew Intlekofer, MD 2016
Memorial Sloan Kettering
Cancer Center

Stephanie Johnson, PhD 2015
University of California,
San Francisco

Neeraj Joshi, PhD 2016
University of California,
San Francisco

Michael Khodadoust, MD, PhD
2015
Leland Stanford Junior University

Seoyoung Kim, PhD 2015
Memorial Sloan Kettering
Cancer Center

Fides Lay, PhD 2017*
University of California,
Los Angeles

I-Ju Lee, PhD 2016
Dana-Farber Cancer Institute

Stanley Lee, PhD 2017*¹²
Memorial Sloan Kettering
Cancer Center

Qiming Liang, PhD 2016
University of Southern California

Michael Lofgren, PhD 2015
Harvard Medical School

Marko Lööke, PhD 2015
Massachusetts Institute
of Technology

Marsilius Mues, PhD 2015
University of California,
San Francisco

Vera Mugoni, PhD 2016
Beth Israel Deaconess
Medical Center

Jagan Muppidi, MD 2016
University of California,
San Francisco

Wen Pan, PhD 2015
Yale University

Jelena Petrovic, PhD 2017*
The University of Pennsylvania,
Medical Center

Lars Plate, PhD 2016
The Scripps Research Institute

Jessica Ridilla, PhD 2015
Brandeis University

Russell Ryan, MD 2017*
Massachusetts General Hospital

Prabha Sarangi, PhD 2016
Dana-Farber Cancer Institute

Anne Schuetz, PhD 2017*
University of Toronto

Srividya Swaminathan, PhD 2017*¹³
Leland Stanford Junior University

Anastasia Tikhonova, PhD 2015
New York University School
of Medicine

Zuzana Tothova, MD, PhD 2016
Dana-Farber Cancer Institute

Peter van Galen, PhD 2017*
Massachusetts General Hospital

Isana Veksler-Lublinsky, PhD 2015
University of Massachusetts
Medical School

Bas Wouters, MD, PhD 2016
Erasmus University Rotterdam

Selwin Wu, PhD 2017*
Dana-Farber Cancer Institute

Heping Xu, PhD 2016
Cincinnati Children's Research
Foundation

Chao Yang, PhD 2016
The Johns Hopkins University
School of Medicine

Joshua Zeidner, MD 2015
The University of North Carolina
at Chapel Hill

Yu Zhang, PhD 2015
Boston Children's Hospital

Hufeng Zhou, PhD 2016
Brigham and Women's Hospital

**Translational Research
Program**

*The Translational Research
Program supports outstanding
investigations deemed by our
expert advisors most likely
to translate basic biomedical
discoveries into new, safe and
effective treatments, ultimately
prolonging and enhancing
patients' lives.*

Ricardo Aguiar, MD, PhD 2017*
University of Texas Health
Science Center at San Antonio

Iannis Aifantis, PhD 2017*
New York University School
of Medicine

Gheath Al-Atrash, DO, PhD 2015
The University of Texas
MD Anderson Cancer Center

Caroline Arber, MD 2016
Baylor College of Medicine

Robert Baiocchi, MD, PhD 2014¹⁴
The Ohio State University

Francesco Bertoni, MD 2017*
Fondazione per la Ricerca e la
Cura dei Linfomi nel Ticino

Bruce Blazar, MD 2015
University of Minnesota,
Twin Cities

Marie Bleakley, MD, PHD,
M.MSC 2017*
Fred Hutchinson Cancer
Research Center

Giulia Casorati, PhD 2016
Fondazione Centro San Raffaele

Lucio Castilla, PhD 2015
University of Massachusetts
Medical School

Leandro Cerchiatti, MD 2016
Weill Cornell Medical College

Li Chai, MD 2016
Brigham and Women's Hospital

James Coghill, MD 2015
The University of North Carolina
at Chapel Hill

Sandeep Dave, MD 2016
Duke University Medical Center

Randall Davis, MD 2017*
University of Alabama
at Birmingham

Madhav Dhodapkar, MBBS 2017*
Yale University

Todd Fehniger, MD, PhD 2017*
Washington University School
of Medicine in St. Louis

Adolfo Ferrando, MD, PhD 2015
Columbia University
Medical Center

Andrés Ferreri, MD 2017*
Fondazione Centro San Raffaele

Mark Frattini, MD, PhD 2015
Columbia University
Medical Center

Paul Frenette, MD 2015
Albert Einstein College
of Medicine, Inc.

Lucy Godley, MD, PhD 2017*
The University of Chicago

Stephen Gottschalk, MD 2016
Baylor College of Medicine

Douglas Graham, MD, PhD 2016
Emory University

Steven Grant, MD 2015¹⁵
Virginia Commonwealth
University

¹⁰ Dr. Jonathan Esensten is fully funded by an anonymous donor.

¹¹ Dr. Charles Gawad is funded in part by Thomas Moore.

¹² Dr. Stanley Lee is fully funded by an anonymous donor.

¹³ Dr. Srividya Swaminathan is fully funded by an anonymous donor.

¹⁴ Dr. Robert Baiocchi is funded in part by Natan Vaisman.

¹⁵ Dr. Steven Grant is funded in part by the Breeden-Adams Foundation.

Dr. Matthew Matasar is funded in part by Gerald Eisenberg.

* Newly awarded or renewed grants in Fiscal Year 2017

Research Grants (continued)

Jolanta Grembecka, PhD 2016
University of Michigan

Timothy Hughes, MD, FRACP,
FRCPA, MBBS 2017*
South Australian Health
& Medical Research Institute

Richard Jones, MD 2015
The Johns Hopkins University
School of Medicine

Emmanuel Katsanis, MD 2017*
The University of Arizona

Michael Kharas, PhD 2017*
Memorial Sloan Kettering
Cancer Center

Yong-Mi Kim, MD, PhD, MPH
2017*
Children's Hospital Los Angeles

Marina Konopleva, PhD 2016
The University of Texas
MD Anderson Cancer Center

Andrew Kung, MD, PhD 2015
Columbia University
Medical Center

Dan Landau, MD, PhD 2017*
Weill Cornell Medical College

Mignon Loh, MD 2015¹⁶
University of California,
San Francisco

Ivan Maillard, MD 2015
University of Michigan

William Matsui, MD 2016
The Johns Hopkins University
School of Medicine

Ari Melnick, MD 2015
Weill Cornell Medical College

Tarik Moroy, PhD 2015
Institut de Recherches
Cliniques de Montreal

Charles Mullighan, MBBS (Hons),
MSc, MD 2017*
St. Jude Children's Research
Hospital

Nikhil Munshi, MD 2016
Dana-Farber Cancer Institute

Markus Müschen, MD, PhD 2014¹⁷
University of California,
San Francisco

Teresa Palomero, PhD 2017*
Columbia University
Medical Center

Antonio Palumbo, MD 2016
Universita degli Studi
di Torino-Dipartimento
di Biotecnologie e Scienze
per la Salute

Javier Pinilla, MD, PhD 2015
H. Lee Moffitt Cancer Center
& Research Institute

Noopur Raje, MD 2017*
Massachusetts General Hospital

Anjana Rao, PhD 2015
La Jolla Institute for Allergy
and Immunology

Feyruz Rassool, PhD 2016
University of Maryland

Katy Rezvani, MD, PhD 2015
The University of Texas
MD Anderson Cancer Center

Alain Rook, MD 2016
University of Pennsylvania

James Rubenstein, MD, PhD 2014¹⁸
University of California,
San Francisco

Ralph Sanderson, PhD 2017*
University of Alabama at
Birmingham

Stefanie Sarantopoulos, MD,
PhD 2016
Duke University Medical Center

Guy Sauvageau, MD, PhD, FRCP
(C) 2017*
IRIC - Institut de Recherche
en Immunovirologie et en
Cancerologie

David Scadden, MD 2017*
Massachusetts General Hospital

Aaron Schimmer, PhD, MD,
FRCPC 2015
University of Toronto

Daniel Starczynowski, PhD 2017*
Cincinnati Children's
Research Foundation

Ulrich Steidl, MD, PhD 2017*
Albert Einstein College
of Medicine, Inc.

Kris Thielemans, MD, PhD 2016
Vrije Universiteit Brussel

John Timmerman, MD 2014¹⁹
University of California,
Los Angeles

Steven Treon, MD, PhD 2015
Dana-Farber Cancer Institute

Amit Verma, MBBS 2016
Albert Einstein College
of Medicine, Inc.

David Wald, MD, PhD 2016
Case Western Reserve University

Roland Walter, MD, PhD 2016
Fred Hutchinson Cancer
Research Center

Y. Lynn Wang, MD, PhD, FCAP
2017*
The University of Chicago

George Weiner, MD 2017*
University of Iowa

Amittha Wickrema, PhD 2017*
The University of Chicago

Catherine Wu, MD 2015
Dana-Farber Cancer Institute

B. Hilda Ye, PhD 2015
Albert Einstein College
of Medicine, Inc.

Qing Yi, MD, PhD 2015
Cleveland Clinic Foundation

Jianhua Yu, PhD 2017*
The Ohio State University

Johannes Zakrzewski, MD 2015
Memorial Sloan Kettering
Cancer Center

Translational Research Program: Renewal

Stephen Ansell, MD, PhD 2016²⁰
Mayo Clinic Rochester

Smita Bhatia, MD, MPH 2016
University of Alabama
at Birmingham

John Crispino, PhD 2015²¹
Northwestern University

Maria Figueroa, MD 2017*
University of Michigan

Ronald Hoffman, MD 2017*
Icahn School of Medicine
at Mount Sinai

James Rubenstein, MD, PhD 2017*
University of California,
San Francisco

Ryan Wilcox, MD, PhD 2016
University of Michigan

MPN Challenge Grants

*This program is run in
partnership with the
Myeloproliferative Neoplasm
Research Foundation (MPNRF).*

Nadia Carlesso, MD, PhD 2016
Indiana University School
of Medicine

George Church, PhD 2016
Harvard Medical School

Camelia Iancu-Rubin, PhD 2016
The Tisch Cancer Institute

Robert Kralovics, PhD 2016
Center for Molecular Medicine
of the Austrian Academy
of Sciences

Zhijian Qian, PhD 2016
University of Illinois at Chicago

Katya Ravid, DSc, PhD 2016
Boston University School
of Medicine

Brady Stein, MD 2016
Northwestern University

Zhaohui Ye, PhD 2016
Johns Hopkins University

Leonard Zon, MD 2016
Boston Children's Hospital

IWMF Grants

*This program is run
in partnership with the
International Waldenstrom's
Macroglobulinemia
Foundation (IWMF).*

Christian Buske, MD 2017*
University of Ulm

Madhav Dhodapkar, MBBS 2017*
Yale University

Marcel Spaargen, PhD 2017*
Academic Medical Center

Special Initiatives

Craig Crews, PhD 2017*
Yale University

Steven Dowdy, PhD 2016^{*22}
University of California,
San Diego - Health Sciences

Ari Melnick, MD 2015²³
Weill Cornell Medical College

Susan Parsons, MD 2015
Tufts Medical Center

Igor Roninson, PhD 2017*
University of South Carolina

Transforming CURES Initiative

John Crispino, PhD 2016
Northwestern University

Reuben Kapur, PhD 2016
Indiana University-Purdue
University Indianapolis

Phillip Koeffler, MD 2016
Cedars-Sinai Medical Center

Akiko Shimamura, MD, PhD 2016
Boston Children's Hospital

¹⁶ Dr. Mignon Loh is funded in part by Cristian Tassin.

¹⁷ Dr. Markus Müschen is funded in part by an anonymous donor in honor of Diane.

¹⁸ Dr. James Rubenstein is funded in part by Leon Borchers, Lisa Scheer Cone & Ed Cone.

¹⁹ Dr. John Timmerman is funded in part by the Rich & Paula Lupen Family Foundation.

²⁰ Dr. Stephen Ansell is funded in part by an anonymous donor.

²¹ Dr. John Crispino is funded in part by the George L. Shields Foundation, Inc.

²² Dr. Steven Dowdy is fully funded by the Dr. Ralph and Marian Falk Medical Research Trust.

²³ Dr. Ari Melnick is funded in part by the Paul E. Singer Foundation Innovation Grant in DLBCL.

Dr. Giridharah Ramsingh is funded in part by Charlotte McCleerey - The Audrey E. Streedain Trust.

* Newly awarded or renewed grants in Fiscal Year 2017

Research Portfolios

New Idea Award

A concept award that funds innovative approaches that may fundamentally change the understanding, diagnosis and/or treatment of blood cancers and related pre-malignant conditions.

Sara Buhrlage, PhD 2017*
Dana-Farber Cancer Institute

Adam de Smith, PhD 2017*
University of California,
San Francisco

Stephen Hedrick, PhD 2017*
University of California,
San Diego

Nora Heisterkamp, PhD 2017*
Children's Hospital Los Angeles

Heiko Konig, MD, PhD 2017*
Indiana University School
of Medicine

Andrew Lane, MD, PhD 2017*
Dana-Farber Cancer Institute

Lev Silberstein, MD, PhD 2017*
Massachusetts General Hospital

Aristotelis Tsigigos, PhD 2017*
New York University

Vaiva Vezys, PhD 2017*
University of Minnesota

George Watts, PhD 2017*
The University of Arizona

Rising Tide Foundation for Clinical Cancer Research/ LLS Patient-Focused Immunotherapy Initiative²⁴

David Gottlieb, MB, MD, FRACP,
FRCPA 2017*
University of Sydney

Ann Leen, PhD 2017*
Baylor College of Medicine

Ronald Levy, MD 2017*
Leland Stanford Junior University

Margaret Shipp, MD 2017*
Dana-Farber Cancer Institute

²⁴ Rising Tide Foundation for Clinical Cancer Research/LLS Patient-Focused Immunotherapy Initiative is partially funded by the Gregory J. Beaudry Family Foundation.

* Newly awarded or renewed grants in Fiscal Year 2017

LLS Research Portfolios are groups of research projects organized around a specific blood cancer interest. The list below includes donors that generously invested in a specific LLS research portfolio during this fiscal year.

Acute Lymphoblastic Leukemia Research Portfolio is funded in part by Terry D. and Carol A. Agness Family Foundation.

Acute Myeloid Leukemia and Myelodysplastic Syndromes Research Portfolio is funded in part by Jonathan Bellobuono & Family and William McNitt.

Chronic Lymphocytic Leukemia Research Portfolio is funded in part by Deborah and Randy Daniels and Tom Kelley.

Chronic Myelogenous Leukemia Research Portfolio is funded in part by Abbeville Family Partnership, S. Lori Brown, Charles Godchaux, Charles Foundation, Becky Godchaux, Dr. Larry and Leslie Nance, James and Judith Wilson and The Salah Foundation.

Hodgkin Lymphoma Research Portfolio is funded in part by the AM Charity Fund.

Immunotherapy Initiative is funded in part by Greg Beaudry and Rising Tide Foundation.

Myeloma and Waldenstrom Macroglobulinemia Research Portfolio is funded in part by The Carlson Family Foundation, The Names Family Foundation and Niles Hushka/KLJ.

Aggressive Non-Hodgkin Lymphoma Research Portfolio is funded in part by American Expediting Company, Dr. Evelyn Bata and The John Wall Family Foundation.

Indolent Non-Hodgkin Lymphoma Research Portfolio is funded in part by Jay and Susan Clark, Grand Chapter O.E.S. DC General Fund and Masonic and Eastern Star Home of the DC Charities, Kirk and Mindy Uhrlaub.

Pediatric and Young Adult Blood Cancer Research Portfolio is funded in part by the ACE Family Foundation (Mary & Michael Levine), Baltimores Orioles Foundation, Thomas and Agnes Carvel Foundation, Rhoda and David Chase Family Foundation, EFESTE Winery, Ella B. Cleveland Trust, Franklin American Mortgage Company, International Right of Way Association, Major League Baseball Players Trust, Team Bright Side, The Wawa Foundation.

Mission Portfolio is funded in part by Ping Y. Tai Foundation, Inc.

Weill Cornell Medicine Specialized Center of Research is funded in part by David J. Grais and Lisa A. Cutler, Scott and Cathy Zeilinger, Escher Foundation.

Quality of Life Research Portfolio is funded in part by The Hamill Family Trust and Hildegarde B. Becher Foundation.

Therapy Acceleration Program is funded in part by The Bryce Foundation, Jean & C.E. Andrews, Cynthia and Joe Bruno, Cora and John H. Davis Foundation, Melryder Foundation, Neil & Emily Kishter, Steve and Beverly Movius, Stacey & Rick Nadeau, Phase Foundation, Ed Quinn, William J. Shaw Family Foundation, The Sleep Family.

The Harry T. Mangurian, Jr. Beat AML Project is funded in part by Richard & Terez Abatecola Foundation Peter Brock, Michael & Liz Copley, Jim Davis, Direct Appeal, Judy Dudley, Anthony and Judith Evinin, FM Kirby Foundation, Harry T. Mangurian, Jr. Foundation, The James H. Reid, Jr. Family, John and Mary Franklin Foundation, JMT Charitable Lead Trust in memory of Chris Hoffmann, J. T. Tai & Co. Foundation, Inc., Ronald Katz, John Kellenyi, Mark Kenyon, Paul D. Leinwand, Steven & Jeannie Lieblich, Quentin Lilly, Jeff Lipscomb, Judy and Charlie Lynch, Clyde McGregor and LeAnn Pedersen Pope, Pamela B. Katten Memorial Leukemia Research Foundation, Ed & H. Pillsbury Foundation, Donald Porteous, Andrea Reid, Robert E. Gallagher Charitable Trust, Robert H. Lyon Leukemia Foundation, Ruth Robinson, Bonnie Magid Roditti, Rogers Family Foundation, ROMA Foundation, Paul & Joan Rubschlager Foundation, Jeff Sachs, John J. Silvestri, Team B Strong, Terry D. and Carol A. Agness Family Foundation, True North Family Foundation, Drenda Vijuk, Virginia Sheldon Jerome Foundation, Mark Weinstein, Family of Cathy Wright, Anonymous.

Endowment Funds

Mary & Robert Bronstein Memorial Fund
 The Virginia Major Brooks Memorial Endowment Fund
 de Villiers Endowment Fund
 Thomas M. Ford Memorial Fund
 GlaxoSmithKline Foundation - Gertrude B. Elion Endowment Fund
 GlaxoSmithKline, Inc. Research Fund
 Jim Jacobs Leukemia Research Fund
 The Rachel Kudish Fund
 Jane Elissa/Charlotte Meyers Endowment Fund
 The Rae Endowment Fund (Ontario)
 Vrushali Ranadive Fellowship Fund
 Reich Endowment Fund
 The UFCW (Canada) Endowment Fund

Partnerships

Therapy Acceleration Program Partnerships

Acetylon Pharmaceuticals, Inc.
 Boston, MA
 Affimed Therapeutics AG
 Heidelberg, Germany
 arGEN-X BV
 Breda, Netherlands
 BioTheryX, Inc.
 Chappaqua, NY
 Ivan Borrello, MD
 Johns Hopkins University
 Sidney Kimmel Comprehensive
 Cancer Center
 Celator Pharmaceuticals, Inc.
 Princeton, NJ
 Christopher Cogle, MD
 University of Florida
 Constellation
 Pharmaceuticals, Inc.
 Cambridge, MA
 Curis, Inc.
 Lexington, MA
 Institute for Applied Cancer
 Science
 The University of Texas
 MD Anderson Cancer Center
 Brian Druker, MD
 Oregon Health & Science
 University
 Mark Frattini, MD, PhD
 Memorial Sloan Kettering
 Cancer Center
 Irene Ghobrial, MD
 Dana-Farber Cancer Institute
 Anand Jillella, MD
 Emory University

Kiadis Pharma NV*
 Amsterdam, Netherlands
 Kite Pharma, Inc.
 Santa Monica, CA
 Holbrook Kohrt, MD, PhD &
 Ronald Levy, MD
 The Board of Trustees of the
 Leland Stanford Junior University
 OncoPep, Inc.
 North Andover, MA
 Daniel Pollyea, MD
 University of Colorado
 Yogen Sauntharajah, MD
 Cleveland Clinic
 Stemline Therapeutics, Inc.
 New York, NY
 Valor Biotherapeutics, LLC
 Dallas, TX

Advisors

Medical & Scientific Advisors

Steven Rosen, MD, FACP
 Beckman Research Institute
 of City of Hope
 Chair
 Stephen Ansell, MD, PhD
 Mayo Clinic
 Rochester, MN
 Leif Bergsagel
 Mayo Clinic
 Scottsdale, AZ
 Ravi Bhatia, MD
 University of Alabama
 at Birmingham
 Alan D'Andrea, MD
 Dana-Farber Cancer Institute
 Giulio Draetta, MD, PhD
 The University of Texas
 MD Anderson Cancer Center
 Philip Frost, MD, PhD
 Irene Ghobrial
 Dana-Farber Cancer Institute
 Catriona Jamieson
 University of California
 San Diego
 Larry Kwak, MD
 Beckman Research Institute
 of City of Hope
 Michelle LeBeau, PhD
 The University of Chicago
 Ross Levine, MD
 Memorial Sloan Kettering
 Cancer Center
 Jonathan Licht, MD
 University of Florida
 Alan List, MD
 H. Lee Moffitt Cancer Center
 & Research Institute
 Alexandra Mayes Birnbaum
 Peartree Communications, Inc.
 Susan O'Brien, MD
 University of California, Irvine
 Franklin O. Smith, III, MD
 Medpace

Therapy Acceleration Program Advisors

A. Dana Callow, Jr., MBA
 Boston Millennia Partners
 Chair
 James Bradner, MD¹
 Dana-Farber Cancer Institute
 Joseph Catino, PhD¹
 Retired from Bayer
 C. Casey Cunningham, MD
 Santé Ventures
 William Dalton, MD, PhD
 M2Gen
 Giulio Draetta, MD, PhD²
 The University of Texas
 MD Anderson Cancer Center
 Ian W. Flinn, MD, PhD
 Tennessee Oncology
 Ross Levine, MD
 Memorial Sloan Kettering
 Cancer Center
 Ronald Levy, MD²
 The Board of Trustees of the
 Leland Stanford Junior University
 Vern Norviel, JD
 Wilson Sonsini Goodrich & Rosati
 Susan M. O'Brien, MD
 University of California, Irvine
 J. Fred Pritchard, PhD
 Celerion

* Equity investment of \$1,000,000
 in Fiscal Year 2016

¹ Ended service in December 2015

² Started service in January 2016

Donors

The below listing is made up of individuals, foundations and corporations that generously supported LLS's mission during this fiscal year.

Leadership Circle \$1,000,000 and Above

The Beer Store
Burlington
Celgene Corporation (PA) (C) (PP)
Genentech, Inc. (PA) (C) (PP)
Gilead Sciences, Inc. (PA) (C)
The Harry T. Mangurian, Jr. Foundation*
Pfizer, Inc. (PA) (C) (PP) (R)
The Olive Garden Italian Restaurant
Pharmacyclics/Janssen Pharmaceutical Companies (PA) (C) (R)
Sarah Cannon Blood Cancer Network
Takeda Pharmaceuticals USA, Inc. & Affiliates (PA) (C)
UFCW
UFCW Canada/TUAC
Drenda Vijak

Champion \$500,000 – \$999,999

Barclays
Bristol-Myers Squibb Company (PA) (C) (PP)
Lang/Stiglitz Family Fund
Rush and Kathryn Limbaugh
The Norcross Foundation, Inc.
In Memory of Herrick F. Norcross, Jr. (Rick)*
Novartis Pharmaceuticals Corporation (PA)
The Paul E. Singer Foundation*
PVH
Salesforce
Anonymous (1)

Visionary \$250,000 – \$499,999

AbbVie, Inc. (PA) (C)
Amgen, Inc. (PA) (C)

BMC
Carter's/OshKosh B'Gosh
Discount Tires Co.
Dr. Ralph & Marian Falk Medical Research Trust
Elbit Systems of America
Global Franchise Group – Great American Cookies®, Marble Slab Creamery®, Maggie Moo's Ice Cream & Treatery®, Pretzelmaker® and Hot Dog on a Stick®
IHOP
Perfumania
Pharma - National
SanDisk
Stater Bros. Charities
Teva Pharmaceuticals (PA) (C)
Walgreens
Wells Fargo
Anonymous (1)

Patron \$100,000 – \$249,999

Alex and Ani
James Allen
Alto-Shaam, Inc.
Alyssa's Crew
The Audrey Streedain Trust
Dr. Evelyn Bata
BDO
Briggs Equipment
Cancer Treatment Centers of America
Charity Golf Outing
Charles Esten's Team Addie
Julia A. Cogburn, MD
The Coleman Foundation*
Michael and Liz Copley*
Cruise Planners, An American Express Representative
EY
F. M. Kirby Foundation, Inc.
Farris Foundation
FIS Foundation
Ethel and Bernard Garil
Goldman Sachs
Imagine A Cure for Leukemia

Incyte Corporation (PA)
Industrial Alliance Insurance and Financial Services
Juno Therapeutics, Inc. (PA) (R)
John Kellenyi
Kite Pharma, Inc. (PA) (R)
KPMG
Jeffrey Kushner
Steven & Jeannie Lieblich
Cristine and Timothy Lindenfelder*
Adrian Marantz and Corin Marantz In Memory of Olga
The Marge & Charles J. Schott Foundation*
Clyde McGregor and LeAnn Pedersen Pope
Mercedes-Benz USA, LLC
Morgan Stanley
NSC Global
Lynne and Greg O'Brien
Orokawa Foundation
Phillips Van Heusen
PhRMA
Donald Porteous
PWC
Nancy and Richard Rogers
Jerry and Lois Rosenblum
Rust Consulting, Inc.
Ryan Family Services LLC
Silicon Valley Bank
Sky Painters
George and Mary Elizabeth Smith
Team Run4Life
Tim Snelson's Pumping Unit Service, Inc.
Kathryn and Leo Vecellio*
Vitas
Marc and Shari Weissbach
Anonymous (2)
**Innovator
\$50,000 – \$99,999**
ABM Onsite Services, Inc.
Acxsys Corporation Interac
All Round Foods Bakery Products Inc.
American Airlines

Amon G. Carter Foundation
Arnold & Itkin LLP
Baker Tilly
Renza Moscatelli Baker
Barclays Bank
Black Dog Charity
Black Tie Affairs Catering Inc.
Peter and Janice Brock
C.J. Coakley Co., Inc.
Camcorp Interest LTD
Daniel Chianese
City of Houston
The Columns Resource Group, Inc.
Comcast Spotlight
Daichii Sankyo, Inc. (PA)
Diamond Wireless
Discount Tire Co.
Earl D. and Marian N. Olson Fund
Charles A. and Trisha Elcan
Enmarket
Faulkner Subaru
Florida Cancer Specialists
Garden City Turkey Trot
Cindy and Brian Gavin
GEICO WNY
Generac Power Systems, Inc.
Jonathan and Mindy Gray
The Hamill Family Trust
Hamilton E. James - James Family Foundation
Hargrove
Pete Harman
The Harry and Jeanette Weinberg Foundation, Inc.
Highland Park Village Marketing Group, LLC
HM Insurance Group
Hoffmann-La Roche Limited
Infor Global Solutions
J&J Development
JDP Mechanical Inc.
John and Frances Beck Family Foundation
Rita Cavanagh and Gerald Kafka
Donald Karpinski,
In Memory of Betty

Neil and Emily Kishter
Jules and Lynn Kroll/K2
Scott and Betsy Krueger
Lehigh Valley Restaurant Group
Paul Leinwand
Lighthouse Investment Partners, LLC
Lundbeck
Judy & Charlie Lynch
Mazda
Medtronic Foundation
Mihuc Trust
Mission Restaurant Supply
Netflix
New York Community Bancorp, Inc.
North Bay Cancer Alliance
Jerry Oakey and Laura Randolph
Pamela B. Katten Memorial Leukemia Research Foundation
Jonathan and Ashley Pappelbon
Penn Medicine
Ping Y. Tai Foundation, Inc.
PRG
PSEG
QEII Health Sciences Centre Foundation
Rhulen Rock Hill Run & Ramble
Riemer & Braunstein LLP
Robert E. Gallagher Charitable Trust
Edgar A. and Ruth E. Robinson
The Salah Foundation
In Memory of Virginia Salah
Harold Salomanowitz Charitable Lead Annuity Trust
Sammons Enterprises
San Par Golf Tournament
Sanofi US (PA)
Sarver Charitable Trust
Linda Schwartzstein and Lee Goodwin*
Sedano's Supermarket
Sempra & Southern California Gas Company
John J. Silvesteri
Solutionreach, Inc.
Sorenson Legacy Foundation

Terragroup, Inc.
Therakos, Inc.
The Thomas J. Perkins and Gerd Perkins Foundation
Timex
Tracy and Ben Lange/Luke's Fastbreaks
Valenti Mid-Atlantic Management, LLC
The Victor E. and Caroline E. Schutte Foundation
Washingtonian Magazine
The Wawa Foundation
The Whitney Foundation
The William Carter Company

Advocate \$25,000 – \$49,999

21st Century Fox
A.C.E. Family Foundation
Agius Pharmaceuticals, Inc. (C)
Allstate Insurance Company
Alverin M. Cornell Foundation
American General Investments, LLC
AMERICAN SYSTEMS
AmTrust Bank - Division of New York Community Bank
Madeline and Stephen Anbinder
C.E. and Jean Andrews
Anthem Blue Cross
AT Corporation T/A IHOP
AT&T
Sidley Austin
Baker Botts LLP
Baltimore Orioles
Baltimore Tour De Court
In Memory of Rachel Minkove

* Denotes multi-year commitment

Pharmaceutical Funding Legend

(PA) Patient Access (R) Research
(PP) Public Policy (C) Campaign

Donors (continued)

Bank of America/Merrill Lynch	Anna and Martin Donlon	John and Kristin Hyland	MorganFranklin Consulting	Southwestern Ohio Wendy's	Acadia Realty Limited Partnership
Barbara Banke	Marian Dozier	IBC Bank - Austin	NARS Cosmetics	St. Joseph's/Candler	Accenture
Joseph Baratta	Driscoll's	ICAP	NASCAR Foundation	St. Juste Management Corp.	Judith and Jon Ackerman
Baylor Scott & White Health	Edgar A. Thronson Foundation	iHeartMedia	The Netter Foundation	Thomas M. Stigers	Acquest Development
BB&T Bank	Edward G. & Kathryn E. Mader Foundation	Ivie & Associates, Inc.	Walter and Ellen Newsom	Mona Carlton Stogner	Ann Milton Adams
Gregory J. Beaudry Family Foundation	EFESTE Winery	J.T. Tai & Co. Foundation, Inc.	Kenneth and Bonni Newton	Subway Restaurants	Samuel Adams
Peggy Beckman	Ahmad El-Dardiry	Charles F. Jacobs*	NFL Foundation	Swedish Health Services	Adobe
Bert Smith & Co.	Eli Lilly & Co. ©	Jefferies	Northrop Grumman	Sylvan/Laureate Foundation	AE Charitable Foundation
Bloomberg	Enterprise Holdings	Jersey Mike's Corporate Advertising Fund	Northside Hospital	Tigerfight Foundation	AM Charity Fund
BMO Harris Bank	EZCORP	The Jim Jacobs Charitable Foundation	Northwestern Mutual	Tommy Hilfiger Corp	AE Solutions
Bernie and Monica Boldt	Faulkner Nissan	John T. Gorman Foundation	Norton Rose Fulbright	Trinity Industries	AECOM Technology Corporation
Bon Secours St Francis	Jonathan Feldman	John Wall Family Foundation	Papa John's	Ultimate Software	Aetna
Booz Allen Hamilton	Carl Fellbaum	John Wall Family Foundation	The Park Foundation	UNC REX Healthcare	Agero
Leon Borchers	Raul and Jean-Marie Fernandez	Johnson & Johnson ©	Paul & Joan Rubschlager Foundation	University of Miami Sylvester Comprehensive Cancer Center	AIG
Michael Borchers	Fidelity Charitable Gift Fund	Joseph & Catherine Johnson Family Foundation	Peck School	UPMC	Air Products Foundation
Braman Miami	Michael C. Fina	Just Give/Cisco	Peoples Natural Gas	Wade Upton	Akin Gump Strauss Hauer & Feld, LLP
Brayton Purcell, LLP	Marilyn Flint	K.S. Adams, Jr. Foundation	Pepeco Holdings, Inc.	Valero	Albrecht Family Foundation
Breeden-Adams Foundation	Flushing Bank	Kaiser Permanente	David and Beverly Pfeifle	Venaleo LLP	Aldridge Insurance
Morris and Pamela Brown	Fox5	Kent's Run	PFG/Vistar	Phil Venables	Alfred P. Tobin Foundation
Joe & Cynthia Bruno*	Franklin American Mortgage Company	The Keri Shull Team	Publicis Health Communications Group	Virginia Sheldon Jerome Foundation	Alliance Data
April and Paul Buchheit	Martin and Sherry Franks	Kilroy Realty, LP	Rally Foundation for Childhood Cancer Research	VWR Charitable Foundation (North Texas)	Allied Solutions, LLC
Carlos Batista Foundation	Furniture Fair	Kritchman Family Foundation	Miles J. Reidy	Walmart	Allmond & Company, LLC
Carlson Family Foundation	GAI Consultants	Landstone Companies	Renate M. Dillon Trust	The Warburg Pincus Society	Alpha Omega Charitable Foundation
Capital One Bank	Gateway Health Partners	Brenda Lavelle	Rendina Healthcare Real Estate	Washington Business Journal	AMC Cares Charitable Fund
CBRE - New England	The Gatorade Company	George Lee	Resource America	Ellen Weissberg	Ameren
Charles McMurray Company	The Gaughen Management Group	Leon Medical Centers	The Rizvi Family	Gloria Weissberg	American Direct Marketing Resources LLC
The Charter Foundation	General Dynamics Information Technology	Lights Out 4 Leukemia INC.	Robert Graham Designs	Mark Weissberg	American Electric Power
City Line Construction	Chris and Patricia Giannoulis	The Lindquist Family Foundation 2005	Melody Rogers	West New York Restoration of CT, Inc.	American Expediting Company
Comcast	Alison Gilmore	Lunardi's Market	ROMA Charitable Foundation	WestOak Developments	Ancira Auto Group
Comedy Central	Global Franchise Group	Luppe & Paula Luppen Family Foundation	Kathleen M. Rosenberg	Wet Willie's Management Corp.	Arthur Andersen
Community Foundation of Collier County John C. Cona Fund	David J. Grais and Lisa A. Cutler	M.A. Mortenson Company	Lisa and Shawn Rosenzweig	Terry Wilds	Anonymous in Honor of Diane
Commerce Bank	Greater Milwaukee Foundation, Inc.	Marsh Risk & Insurance Services	Jason Ryan	William R. Rich Foundation	Anonymous in Honor of Jill Gillette
Community Foundation Sonoma County	Eric and Rachel Green	Matthew and Kim Mausser	Jeffrey D. Sachs*	Woolf Farming and Processing	Aon Risk Solutions
Community Medical Centers	Thomas E. Hancock	MAXIMUS Foundation	Pat and Jeff Sachs	WTOP Radio	AppLovin
Beidre Cosby	The Handlery Foundation	Merchandise Pickup Service, Inc.	Sarah Cannon HCA Midwest Health Blood Cancer Network	Adelaide W. Zabriskie	Aqueduct Technologies
Cottrell Family Foundation	HCA Foundation	Merck & Company, Inc. ©	Stephen Scherr	Scott and Cathy Zeilinger	Ariad Pharmaceuticals, Inc. ©
CyberLock Inc.	Hildegard D. Becher Foundation Inc.	Susanna L. Merriman In Loving Memory of Brian Merriman	Seattle Genetics, Inc. (PA)		Charles and Kate Arnold
Dana Farber Cancer Institute	AI Hill, Jr.	Metromont Corporation	Security Service Federal Credit Union*	Giving Circle \$10,000-\$24,999	Arthur J. Gallagher & Co.
Danford Foundation	J. Tomilson and Janine Hill	George Meza	Bart Sichel	225 Fourth LLC	ARUP Laboratories
David Yurman	Hitz Foundation	Miles & Stockbridge	Sidley Austin LLP	Abacus Technical Services, LLC	Associated Credit Union
Deloitte	David Hitz	Robert Moore	Sandra Sinclair	ABC 7/WJLA-TV	Assurant Specialty Property
Dian Graves Owen Foundation		Thomas Moore	Paul Singer	Daniel Abeln	Astellas Pharma US Inc.
DLA Piper LLP					Astex Pharmaceuticals ©
Don C. & Diane S. Lake Family					

At Home	Keith Block	Jeffrey and Jennifer Butler	The Chesney Miles Charitable Fund	Community Health Charities	David and Jill Israel / Sessions, Fishman, Nathan & Irsael, LLC
Athletic	Bloomberg	C. Kenneth & Laura Baxter Foundation, Inc.	Chiaramonte Construction Company	The Community Foundation for the National Capital Region	David M. Polen Retirement Plan Trust
Atlas Research	Blue Cross & Blue Shield of Mississippi	C.H. Robinson Worldwide	Child's Play Therapeutic Homecare	comScore, Inc.	Donald W. Davis
Avanade	BlueCross BlueShield of South Carolina	Mary Cahill	Choate Construction Company	Community Justice Foundation	James Davis, PhD
Avnet	BlueCross BlueShield of Tennessee Health Foundation	Caliber Collision	Chrane Food Service	Lisa Scheer Cone & Ed Cone	Deans Knight Capital Management Limited
Mr. and Mrs. James Axelrod	Brad Blumenfeld	California Resource Corporation	Chris Hoffmann Memorial	Continental Resources, Inc.	Dechert LLP
B&R Property Management	The Blumenfeld Family	Dillon Cameron	Donald W. Chrisman	Lisa and Clay Cooley	Dell - Silicon Valley Community Foundation
Dean Backer	BMC Houston	Capgemini US LLC	Mary Christman	Cora & John H. Davis Foundation	Deltek
Ball Corporation	BMHC Corporation	Capital City Bank	Chucky's Champions Inc.	Cordia Partners	Scott Dennett
Ian Batchelor	Bocina Homes	Capital Pacific	Justin Chueh	Courtney Knight Gaines Foundation	Destination Wealth Management
Brian and Michaelle Bahnsen	Boies, Schiller & Flexner, LLP	The Capoccia Family	Church & Dwight Employee Giving Fund	Crane Fund for Widows and Children	Dickinson Fleet Services LLC
Jerome Bailey	James Boland	Captains Memorial Foundation	Cigna Foundation	Crazy for a Cause Charity Fund	John Diclemente
Jefferson Bank	Katherine Boodt	Carbide Concepts Company LLC	Cisco - Americas Partner Marketing	Credit Suisse	Robert Dierberg
The Barbara and William Rosenthal Family Foundation	Boston's Best Coffee Roaster	Mr. and Mrs. Michael W. Carraway	Citco	Vick Crespin	Tina Dimeo
John E. Barbey	Marg Boutilier	CareFirst BlueCross BlueShield	Citrix Systems	Cricket Wireless	Dittmar Company
Paul Barnhart	John Boyle	Caribbean Property Group	CKE Restaurant Holdings, Inc.	Cromar Foundation	DLE Equipment
Barry's Bootcamp San Francisco	Penny A. Bradley	Carl Marks & Co.	Clair Global	CrossCountry Consulting	Christian Dodder
Mike Bartschat	Chris Brady	Kristen Axelsen Carmel and David Carmel	Clark Construction Group, LLC	Crown Holdings	Dodge Jones Foundation
Sandra Atlas Bass	Braman Motorcars	Chris Carlos	Dan Clark	Cruise Industry Charitable Foundation	Jayne & Timothy Donahue
Bath Fitter	Brandywine Realty Trust	Carney Family Charitable Foundation	Jack Clark	CSG International	Jason Donnor
Steven Bautista	Bravelets LLC	Carnival Foundation	Jay and Susan Clark	CSI Leasing	Dorothy D. Smith Charitable Foundation
Baxalta, Inc. ©	Richard Bready	Carol A. Stuhr Family Foundation	Michael Clark	CSRA Inc.	Drake Real Estate Services, Inc.
BBVA Compass Bank	Bridger Management, LLC	Kelsey L. Carr	Harland Clarke	CTI BioPharma ©	Joel and Tricia Drake
BD Biosciences	Alan Briggs	Carroll Services, LLC	Clarkson Eyecare	The Culp Family Foundation	Duane Morris, LLP
BD Canada	Dennis Briggs	Andrew Carter	Clayton Tile Distributing Co, Inc.	Cure it With Corn	Michael & Renee Duncan
Beacon Capital Partners	Broadridge Financial Solutions	Steve Carter	Clearview Cancer Institute	Cushman & Wakefield	Timothy and Samantha Durst
Beacon of Hope Hospice	Andrew Brock	Jim Cayton	Clifford W. Illig Revocable Trust	CVS Health	E M A Hainsworth Family Fund
Bear Construction Company	Brown & Gould	CBIZ and Mayer Hoffman McCann	Clothes Mentor/Plato's Closet/Once Upon A Child	CW & Dorothy G. Love Foundation, Inc.	The E Group
Jonathan Bellobuono	S. Lori Brown	CDI	Clover Stornetta Farms	CW Capital	E.E. Reed Construction, L.P.
Bender Foundation	Craig Browning	CDW	Clune Construction Company	D3 LLC Gold Sponsorship	The Earl and Brenda Shapiro Foundation
Gideon Berger	Joe and Cynthia Bruno	Centene Corporation	Coastline Food Services Corporation DBA Wendy's	Ashley and Alan Dabbieri	Eastdil Secured, LLC
Berkshire Bank	William Bryan	Centric Group LLC	The Cobb Foundation, Inc.	Jennifer Dahlberg	Eckert Family Charitable Foundation
The Bernal T. Chomeau Private Foundation	Bryan Cave LLP	Century Elevator Maintenance Co.	Lawrence "Doc" Cohen	The Dan and Jacqueline Lion Family	
Michael Bernot	The Bryce Foundation	Cerner Corporation	Cohn Family Foundation	Danaher Corporation	
Beta Engineering	Buffalo Yacht Club	CFO Strategies	Ron Cohn	Cathy Cunningham	
Stacey Biagi	Semih Bulat	The Chambers Foundation	CohnReznick LLP	Thuy and Mitch Dancik	
Marc-André Bibeau	Jeff Burch	Chapin Davis Foundation	Cole, Scott & Kissane P.A.	Jamal and Rania Daniel	
Bill and Fern England Foundation	Burke Family Foundation	Charles Foundation and Becky Godchaux	Comm/Fidelity Charitable Gift Fund	Randy and Deborah Daniel	
Bill and Melinda Gates Foundation	Stephen Burke, DDS MS, Inc.	Chase Bank	Community Foundation of New Jersey	David Adams Memorial Fund	
Biotechnology Innovation Organization	Burlington-Des Lacs Elementary School	Charles & Diane Cheatham			
Bisnow	Keith Busse	Amy Cherubini			
The Blackstone Charitable Foundation	Butler Family Foundation				

* Denotes multi-year commitment

Pharmaceutical Funding Legend

PA Patient Access	R Research
PP Public Policy	C Campaign

Donors (continued)

Eckert Seamans Cherin & Mellott, LLC	Fit2Run	George L. Shields Foundation, Inc.	Haselden Construction	Independent Health	June & Cecil McDole Charitable Fund
Eckrich - John Morrell Food Group	Annie Flaig	Georgia Cancer Center at Augusta University	Diana Haverstick	Index Fund Advisors, Inc.	The June and Cecil McDole Charitable Fund
Edge on Hudson	The Florence O. Hopkins Charitable Fund Inc.	Georgia Power Company	Hazmat/Kenworth	Index Ventures, Inc.	The Kahan Family
Edith M. Schweckendieck Trusts	Florida Panthers	GetWellNetwork, Inc.	Health Partners Inc.	The Indiana B. Langston Fund (Mr. and Mrs. Winlow M. Heard, Trustees)	Sandra and Stan Kahan
Edward Jones	Florida Power & Light Co.	Jeffrey Giampalmi	HealthONE	Infinity Pharmaceuticals ☺	Kaltenbacher Family Foundation Inc.
Sandy Edry	FMC Corporation	Steven Glenn	HealthONE/Presbyterian St. Luke's	Infosys	Robert Kane
Edward B. Dunlap, Jr. Foundation	FollowDavidMo	The Glick Family Foundation	Heartland Blood Centers	Ink Technologies	Susan and Daniel G. Kane
Janet Edwards	Ford - UAW	Global Traveler Magazine	HEB Grocery Company	INO	The Karyn Research Fund
EKS&H	Bob Ruth Ford	Sandi Gluck	Mark Heese	InquisIT	Kasasa
Ella B. Cleveland Trust	Forest County Potawatomi Foundation	David Gochman	Kathleen Helge	Insulators International	Kathy Wilson - Rachel's Kitchen
Element Financial Corporation	Fourteen Foods	Diana Goldberg	The Helis Foundation	Health Hazard Fund	Ronald C. Katz
Elks of Los Angeles Foundation	Fox Chase Cancer Center	Gold Coast Plastic Surgery LLC	Josh Hellstrom	Intec Group, Inc.	KCE Structural Engineers
David Elliott	Fox Valley Hematology & Oncology	Dr. Donald and Marion Golden	Gayle and Jeffrey Helman	Interactive Data	Keeler Motor Car Company
Ellis & Ellis	Fragrance Resources, Inc.	Golf & Tennis Pro Shop, Inc.	Help Save Matthew Fund	Intevac Inc.	Keller Williams
The Elpis Foundation	Franklin Township Middle School West	John and Kitty Goodish	Tom Hendren/Array Marketing	Iron Bow	The Kenneally Family
Emerson Charitable Trust	Fred Smith Plumbing & Heating Co.	John and Mary Franklin Foundation, Inc.	Monica & Tim Henkel	Sharon Kay Ivie	Kent Island American Legion
The Emerson Group	Frederick and Margaret L. Weyerhaeuser Foundation	Keith Gordon	Henkels & McCoy Inc.	J. E. Fehsenfeld Family Foundation	The Kerins Family
EN Engineering, LLC	Zachary Freeman	Gosling's	Hewlett-Packard Enterprise	J+J Shared Services	Gloria and Richard C. Kerns
EnerVest Ltd.	Freson Bros.	Grand Rounds	Jeffrey M. Hewson	Jack Henry & Associates	Kelli Ketcham
Enterprise Rent-A-Car	Fresno/Clovis New Car Dealers Association	Grange Insurance Companies	Russell C. Hibbeler	Jag Trucking, Inc.	Bob & Charlotte Kettler
Epic	Stroz Friedberg	William E. Greehey	Highmark Blue Cross Blue Shield	The James H. Reid, Jr. Family	King & Spalding
Epizyme, Inc. ☺	Frost Bank	David Green	David Hill	Raymond James	Tom Kingsbury
ePlus Technology	FTI Consulting	John Reginald Hill	Donnie & Marcie Hill	Janney Montgomery Scott	Larry Kitahara
Equestrian Sports Productions	Sameer Gandhi	Hillary Scott Business	John Reginald Hill	Brian Jaramillo	Charles Kiven
Erie Insurance Co.	Garaje Isla Verde	Cynthia Hinojosa	Hillary Scott Business	Jared Coones Memorial Pumpkin Run	Penney and Gerry Klingman
The Escher Foundation	Israel Garcia	HMG Healthcare	Hogan Lovells	The Jay and Rose Phillips Family Foundation	Kolache Factory
ESPN980	Gardner Family Trust	Hogan Lovells	Rick Hoagland	Jazz Pharmaceuticals Inc. ☺	BJ & Carrie Knapp
Exergy	Annabelle Garrett	Hogland	Honored Hero Run	JE Dunn Construction	Chris Kolb
Exp. US Services Inc.	Gary & Pennie Abramson Charitable Foundation	Howard	Steve Hornsey	The Jeannette and H. Peter Kriendler Charitable Trust	Koons Tysons Toyota
Express Scripts, Inc.	Cynthia and Frank Gasztonyi	Howard Hedinger Foundation	Houston Methodist	Jerry Durant Auto Group	R. Patrick Krause
Faisal Rehman Medicine Professional Corporation	Chris A. Gautreau	Howard Labkon	Howard Burris	Jewish Community Foundation	Barbara Kreitzer
Elizabeth Fath	Geico	Eric Hoxsie	Howard Family Foundation	Jim Healy Family Charitable Gift Fund	Geraldine and Charles F. Kriser
Ann Fatzinger	General Dynamics Mission Systems	HP Houston	Howard Hedinger Foundation	John G. Rangos, Sr. Charitable Foundation	Kroger Co. Foundation
Edward Fein	Genpact	Huffington Foundation	Howard Hedinger Foundation	John Muir Health	The Kroll Family Foundation
Dr. Alan Feiner	George and Mary Josephine Hamman Foundation	Huntsman LLC	Howard Labkon	John Theurer Cancer Center	KU Endowment
Felicia & Arnold Aaron Foundation	George F. & Myra Shaskan Foundation	Niles Hushka/KLJ	Eric Hoxsie	Christopher A. Johnston	KU School of Pharmacy-Student Organizations
Ferrari of San Antonio		HyVee, Inc.	HP Houston	Jones Day - Houston	Dave Labuda
Fike Corporation		IBERIABANK	Huffington Foundation	JP Morgan Chase	La gang à garçon
FIMF, Inc.		Imagenet LLC	Huntsman LLC	Julian Ceramic Tile Inc.	Ladish Co. Foundation
Findlay Honda Henderson - SNV		Independence Blue Cross	Niles Hushka/KLJ		Michael and Kathy Ladra
First NBC			HyVee, Inc.		Eddie Lafferty
First Niagara			IBERIABANK		Lake Family Foundation
Michael Fisher			Imagenet LLC		Lantern Wealth Advisors LLC
			Independence Blue Cross		

The Lappin Foundation	Chuck Malk	Merrill Lynch, Neat, Redpath, & Spaeth Wealth Management Group	Names Family Foundation	Oxford Development Co.	Porsche of Annapolis
Scott LaRoque	Mallinckrodt, Inc. (RM)		Larry and Leslie Nance	Ostroff Associates	Ports America
Latham & Watkins	Manatt Phelps & Phillips, LLP	Doug and Kersten Meyer	National Cooperative Services Corporation	Pacific Service Credit Union	PRA Health Sciences
The Laverna Hahn Charitable Trust	Mariner Real Estate	Massachusetts General Hospital Cancer Center	National Neuromonitoring	Pacific Union	Precision Manufacturing Co., Inc.
William Lawlor	Lois Markovich	Miami Cancer Institute	Cooperative Finance Corporation	Palantir	Presidio
Daniel & Karen Lee	The Marksmen Company	Miami Parking Authority	Navarro Discount Pharmacies	Jim and Gail Palmer	Steven and Linda Priddy
Legal Placements, Inc.	Marsh Supermarkets, LLC	Michael Sweig Foundation	Navarro Family Foundation	Park Place Dealerships Park Place Dealerships	Priority Physicians
Lehman Millet Incorporated	Bruce and Electra Martin	Mike Woolf Farming Company	Nestle Purina PetCare Company	PathGroup, Inc.	Donald Proctor
Judi Leonard	Marylou's Coffee	Milbank	NetApp	The Paul B. Greetin and Beryl S. Greetin Foundation, Inc.	Provision Health Alliance
Leon S. Peters Foundation	Mashkin Family Foundation	Bruce Miller	New York Community Bank	Pauline Allen Gill Foundation	The Pumping Stations, Inc.
Lewis & Bockius LLP	Masonic & Eastern Star Homes of the District of Columbia Charities	Stephen Miller	Newmark Grubb Knight Frank	Laura Taft Paulsen	Kevin Putnam
AJ Lewis Jr.	Massapequa Turkey Trot, Inc.	Richard Mines	News4WOAI/Fox29/CW35	Peake BMW	PVH (Tommy Hilfiger)
Liberty Mutual	Massapequa Youth Lacrosse Club	Mingledorff's Inc.	Nimble Storage	Lauren Pearson	Quest Diagnostics
Liberty Property Trust	MasterCard	Sunil Mishra	Niraj and Jill Shah/FCGF	Peck, Madigan, Jones & Stewart Inc.	Ed Quinn
Mary & Lawrence Liebscher	Ken Matherne	Mitsubishi Hitachi Power Systems of America	NOCO	Pegasus Builders, Inc.	Quintiles
The Lipman Family	MB Financial	Mobile Beacon	Nomura Securities International	Penn Color	Quiznos Canada
Pam Littlewood	Daniel McBride	Lori Mody	North American Partners In Anesthesia	Pennant Foods Corporation DBA Wendy's	Rabobank
Julia & Dennis Lincoln	Thomas McCarthy	Moglia Family Foundation	North Napa Rotary Club	Pennock Acheson Nielsen Devaney	Isicoff, Ragatz & Koenigsberg P.A.
Connie L. Lindsey	Henry and Alta McCrary	Molson Coors Canada	North Sails	Pennsylvania Wireless Association Inc.	Rambus
Kim and Jim Lites	Will & Emery McDermott	Monticello Spring Corporation	Northwell Health	Performance Automotive Network	Russ & Norma Ramsey
Locke Lord LLP	William McGee	Patrick M. Moran	Northwest Hope Foundation	Perfumania, Inc	RAST Foundation
Lockton Companies	Sean and Erin McGould	Donald Moreau	The Northwest Company, LLC	Reuben Foundation	Raynier Institute & Foundation
Logicalis	Jeff McGrath	Kevin & Charity Moreland	Nova Restoration	Reece Holbrook Win Anyway Foundation Inc.	Red Robin
Lokai	McKesson Specialty Health	Morgan Borszcz Consulting	NPL Construction Company	Jesse Regan	Rambus
David Longo	John & Kathy McKinley	Morgan, Lewis & Bockius LLP	NuStar Energy and The Greehey Family Foundation	Reily Foods Company	Russ & Norma Ramsey
Longwell Family Foundation	McKinsey & Company	Marcie and Jay Morrison	NWN Corporation	Cambria and Brian Reinsborough	RAST Foundation
The Lotz Family Foundation	The McLelland Family Foundation	Tommy Morrison	Morgan O'Brien	Republic Finance, LLC	Raynier Institute & Foundation
Louie's Wine Dive	McNichols Family Foundation	Judge and Ali Moss	Oddo Development	James Resnick	Red Robin
Low Book Sales	William McNitt	Motorola Solutions Foundation	O'Donnell Honda	Resolution Run to Kick Cancer Inc.	Reece Holbrook Win Anyway Foundation Inc.
Lucy Martin and Family In Memory of Ron Martin	Debbie and Danny McQuary	Steve and Beverly Movius	Office Environments International	Reuben Foundation	Reece Holbrook Win Anyway Foundation Inc.
Lumina Foundation	MD Anderson Cancer Center	Phillip Moy	Offshore Sailing School	Thomson Reuters	Reece Holbrook Win Anyway Foundation Inc.
Luther Westside Volkswagen	Laurie Vest-Meader	MSC Industrial Supply Co.	The Ohio State University Comprehensive Center	Rex 3, Inc.	Reece Holbrook Win Anyway Foundation Inc.
Kent M. Lynch	MediaLocate, Inc.	Mufiz and Chauhan Foundation	Arthur G. James Cancer Hospital and Solove Research Institute	The Rhoda and David Chase Family Foundation, Inc.	Reece Holbrook Win Anyway Foundation Inc.
M&T Bank	MedImmune, LLC	Bruce Muirhead	O'Keefe Lyons & Hynes, LLC	The Rhode Island Foundation	Reece Holbrook Win Anyway Foundation Inc.
Mabee/Gumpert Philanthropic Fund	MedSummit Solutions	Elizabeth M. Mungo	Pamela Oles	Richard & Terez Abatecola Foundation	Reece Holbrook Win Anyway Foundation Inc.
Mack Madness, Inc.	Megan's Wings Inc.	Adrian Munoz	The Omer Foundation		Reece Holbrook Win Anyway Foundation Inc.
Margaret Madden	Melryder Foundation*	Pamela and Byrne Murphy	Oncology Hematology Care, Inc. (OHC)		Reece Holbrook Win Anyway Foundation Inc.
Albert Magid	Otilia Melwani	Muy! Pizza Huts	OneSource Distributers		Reece Holbrook Win Anyway Foundation Inc.
Magnum Power Products LLC	Memorial Healthcare System	Darryl Myers	Oregon Health & Sciences University		Reece Holbrook Win Anyway Foundation Inc.
Gerard and Joyce Magrini	Alejandro and Evelyn Mendieta	n2grate Government Technology Solutions	Peter O'Sullivan		Reece Holbrook Win Anyway Foundation Inc.
Robert Maher	Merchant Choice Payment Solutions	Rick and Stacey Nadeau*			Reece Holbrook Win Anyway Foundation Inc.
Major Hyuandai	Mercy Health Partners - SWO	The Nagula Foundation INC			Reece Holbrook Win Anyway Foundation Inc.
Major League Baseball Players Trust		NAI Miami			Reece Holbrook Win Anyway Foundation Inc.

* Denotes multi-year commitment

Pharmaceutical Funding Legend

PA Patient Access	R Research
PP Public Policy	C Campaign

Donors (continued)

Nina Richardson	Sang pour sang asiatique	Snelson's Natural Gas	Tat Kwok	Brian Tyll	Washington Executive Association
Rick Hendrick Chevrolet	SAS	So Long to Leukemia	Tata America	Jean and Wallace Tyner	Washington Gas
Rifenburg Construction	John Saunders	Anthony Soave	Ann Taylor	U.S. Chamber of Commerce Foundation	The Washington Redskins
Cindy and Steve Rigby	Savills Studley, Inc.	Shahan D. Soghikian	Teachers and Tutus	UBS Financial Services Inc.	Waste Technology Services Inc.
Julianna Riley	Sawnee EMC	Sorenson Media, Inc.	Team Annie Rose Foundation	UCSF Bernioff Children's Hospital	Ken Waterhouse
Riptide Property Maintenance, LLC	Scheid Family Wines	Southeastern Development Association	Tech Data	UFCW Local 75	Wawanesa Insurance
Rising Capital Associates, LLC	Ivan Schlager	Southern Proper Hospitality, LLC	Techstar	Uhlig LLC	Waxman Strategies
Riverstone Resources LLC	Robert Schlegel	Mark and Carol Spisak	Tee Off Against, Inc.	Mark Uhlig	Web Marketing Associates
RNDC South Carolina LLC	Robert C. Schmidt	Splunk, Inc.	Teligistics, Inc.	Kirk and Mindy Uhrlaub	Dave and Kathie Weber
RoadID	Schneider Mitola, LLP	Sprout Loud, Media Networks	Teneo Strategy LLC	Ulm Family Foundation	The Wedell Family Foundation
Robert and Jenny Kottler/IBERIABANK	Jeff and Denise Schwendeman	Sprouts Chula Vista	Terakeet LLC	The Ultimate Software Group, Inc.	Visse Wedell
Robert H. Lyon Leukemia Foundation	Scott Stankavage Family Fund of Triangle Community Foundation	Gretchen Stangier	Terry D. & Carol A. Agness Family Foundation Trust	Unanet	WEDO Auctions LLC
Robert Half International, Inc.	Sedgwick	Phil Steel	Terumo BCT	The University of Kansas Cancer Center	Christopher Weiler
Ruth E. Robinson	Mark Seltzer	Steele Resources, LLC	Texas Capital Bank	United Properties Brokerage LLC	The Weiler Foundation
Rock Spring Contracting, LLC	Sempra Energy Foundation	Mr. and Mrs. John M. Steele	Texas Instruments	United Security Bank	David D. Weinstein
The Roderick Seward, Flossie Radcliffe and Helen M. Galloway Foundation, Inc.	Joe Sergi	Takeda Oncology	Texas Oncology	United Way of Greater Milwaukee	Weldon Service & Repair
Bonnie Magid Roditti	Setton Farms	Todd and Diana Stiefel	The Thalia N. Carlos & Chris M. Carlos Foundation	United Way of San Antonio and Bexar County	Chris Welling
Rogers Family Foundation	Settlement Alliance	Todd Reed McClintock Memorial Research Fund	Larry Thayer	The University of Michigan	WellHealth Quality Care
Rohde & Schwarz	Jerry Shae	Stingray Capital Partners I LLC	Thomas and Agnes Carvel Foundation	US Bank	Christopher Welling
Ronald & Joynce Wanek Foundation, LTD.	The Shawver Family	Sean Stout	Judy and Michael H. Thomas	Natan Vaisman	Wells Fargo Foundation
Rose Community Foundation	Shearman & Sterling, LLP	Strategic Products and Services	Thompson Habib & Denison Inc.	Vanda Pharmaceuticals	West Marine
Kevin Rose	Sherrard Kuzz LLP	Strategic Property Partners, LLC	Tim and Sarah Jur Foundation	Seth and Mari Vasan	Westchester Triathlon Committee
Round Rock Management, LLC	Shulman, Rogers, Gandal, Pordy & Ecker L.P.	Gabriel Stricker	Tin Lizzy's Cantina	Venari Resources	Penny Westfall
Royals Charities	Bart Sichel	Subaru of America, Inc.	Tishman Construction	Linda Verkruyse	Beth Wilkinson & David Gregory
RPA Advisors, LLC	The Sidney, Milton and Leoma Simon Foundation	Sugar Creek Packing Co	Tishman Speyer	Lois Vick, In Memory of Myrtle Mayala Flaa, Tom Vick and Chris Hoffmann	George T. Wilkinson
RPM Mortgage	Simon Foundation	Sullivan & Cromwell LLP	Title Associates	Vidaris, Inc.	Willco
RPM Pizza (Domino's)	Judy and Albert Simon	Patrick and Pam Sullivan	Tito's Handmade Vodka	Videx Inc.	William G. Pomeroy Foundation
Christopher Russell	Susan Simon	Sun Trust Bank	Tom & Virginia Jennaro Family Foundation, Inc.	Vinson & Elkins LLP	William J. Shaw Family Foundation
Jim Ryan	Barrie H. Simonson	Sunesis Pharmaceutical	Bruce Torrance	Visa USA	Williams & Connolly LLP
Safeway Foundation	Beth and Fred Singer	SunGard	Dan Towriss	VITAS Healthcare	Willis Towers Watson
SAIC	Siteman Cancer Center	Sunlight Supply	Transcore	VWR Charitable Foundation (Eastern Pennsylvania)	James Wilson
Sailing World	Shade Tree Services Co.	Suntrust Foundation	Transnational Bankcard, LLC	The W. O'Neil Foundation	Winston & Strawn LLP
John and Lauren Salata	Skadden, Arps, Slate, Meagher & Flom, LLP	Susan G. Komen For the Cure	Transwestern	W.K. Beattie Holdings Ltd.	Thomas Witzemberger
Greg Sales	Skanska	Susan and John Thompson Family Fund	Larry and Nicole Treen	The Walking Company	WIVB-TV, Channel 4/CW 23
David Salinas	SL Green	Swan & Legend	Lee Tepper and Dorine Real	Walgreens Region 19 - Impact Award - "Acute Lymphoblastic Leukemia research in the honor of Aamina Green"	Michael T. Woolf, DDS
Samuel C. Cantor Charitable Trust	The Sleep Family	Bill Sweedler	Trion	The Walls Family	World Care
San Antonio Automobile Dealers Association/Texas Automobile Dealers Association	Small Army For A Cause, Inc.	Jerry Sweeney	Gary and Angela Trovato	Nate and Katherine Ward	Washington Prime Group
San Diego Sign Company	Dee Anna Smith	Swing Fore The Cure	Troy Savings Bank Music Hall	Daniel Warmenhoven	Yahoo Employee Foundation
Curtis Sandoval	Douglas and Phyllis Smith	Timothy Talbot	True North Family Foundation	Peggy S. Warren	Yogurtland
	Kristie Smith	Anne Tally	TrueNorth		Eric, Tamara, and Nicholas Yollick
	Melissa Smith	Rohan Taneja	Kevin and Kristen Tu		Youman, Madeo & Fasano
	Mike and Sue Smith	Jeffrey Tannenbaum	TurningPoint Global Solutions, LLC		Zappos.com
	SMP	Jack Tarditi	Renee & Larry Twersky		The Zenith Insurance Company
		TAS Foundation			Zodiac Inflight Innovations
					Joseph Zvesper
					Anonymous (7)

Top Campaign Fundraisers

Schools that have raised more than \$25,000, individuals who have raised more than \$50,000 or companies/teams that have raised more than \$100,000 to support LLS's mission.

\$5k Club 2016
 55 Reasons: To Live, To Give!
 Jessica Aldridge
 Alex Pascual's Campaign Team
 Asif Alikhan
 Ruben E. Alvarez
 Krista Alwine
 Halleigh Amsden
 April Ancira
 Maeden Anda
 Brittany Anderson
 Loch Anderson
 Erica Andrew
 Angela Tatum
 Anna Donlon & Team Imagine
 Robert Ashby
 Dave Athwal
 Attack 4 Jack
 Stu Baker
 Bank of America
 Barclays
 Paul Barnhart
 Lee Bates
 Cromwell Baun
 Bea Cured
 Chris Beazer
 Stephen Beckwith
 Carl Bedell
 Robert F. Bellizzi
 Eric Bencivenga
 Michelle Jordan-Berndt
 Scott Bernstein
 Dr. Brian Berryman
 Beverly Brea's Campaign Team
 (In Memoriam)
 Stacey Biagi
 Big Rich's Team
 Chris Bird
 The Blackstone Group

Blood Busters: Funding Blood
 Cancer Cures
 Bloomberg
 Brad Blumenfeld
 Dr. Ann A. Bockrath
 Kim Boerman
 Abigail Boldt
 Mirka Bolton
 Jon Bonnell
 Lexie Boudreaux
 Carla Brems
 Brent Hagey's Campaign Team
 Derek Brock
 Jennifer Brody
 John Brookbank III
 Michael Brooks
 Kristin Brotherton
 Morris Brown
 Craig Browning
 William Buckley
 Britoni Burdett
 Ian Burnett
 Burlington Des Lacs
 Elementary School
 Amanda Bush†
 Danny Callahan
 Ace Calvert
 Robert "Spider" Cantley
 TJ Caplinger
 Kelsey Carr
 Carter's
 Rich Catan
 Daniel Chianese
 Elizabeth Childers
 Jim Chrisman†
 Christina Diehl
 Chad Clardy
 Andrew Clark
 Michael Clark
 M. Preston Clarke
 Greg Clary
 Clearwater Middle School
 Julia Cogburn, MD
 April Cohen
 Brianne Cohen
 Ron Cohn
 Michael Colen
 Tom Collins

Colton's Army
 Jason Cowan
 Jennie Crandal
 Darris Crandal
 Credit Suisse
 Mathew Cromar
 DeAnna Crosby
 Michelle Crossland
 Cycle For Life
 Katie Daily
 Nolana Mymka Daoust
 Dare to Care
 Michael G. Dash
 David Stone & Team JAMEN
 Genevieve Dean
 Tori Deatherage
 Stephanie DeFreese
 Joseph DeSabia
 Surrinder P. Dhillon
 Brian Diaz
 Christina Diehl
 Discount Tire
 Kathy Disher
 Disney Team MA Chapter
 Brian Domingos
 Matthew Donaldson
 Tam Driscoll**
 Dr. Greg Eberhart
 Brittany A. Edelmann
 Elex Michaelson & Team
 "We're All In It Together"
 David Erwin
 Vikki Evans
 Beth Faiman, PhD
 Geri Farr
 Katherine Ferguson
 Mary Figura
 Valerie Fiordillino
 Michael Fisher
 Matthew Flinchbaugh
 Florida Power & Light
 Sam Forrest
 Christopher G. Foy
 Richard Gaff
 Geico
 Jessica Gianulias and
 Natalie Woodruff

The Glew Family
 Steve Golden
 Goldman Sachs
 Dan Goodrich
 Grandma's Marathon Team - MN
 Chapter
 Maria Grasso
 Mark Greco
 Bobby Green
 Mary Guzek, DMD
 Brianna Haag
 Chris Hadermann
 Brent Hagey
 Janet Harden
 Amelia Harper
 Helen Harris
 Chad Harthan
 Bill Hauser
 Cathy Hebling Peduzzi
 Jennifer Heckler
 Heidi Netzley & Team Happy Feet
 Christen Heye
 Sean Hieter
 Leslie Himley
 Holli Hines Easton
 Chrissy Hixson
 Brandon Hoehn
 Carolyn Hoover
 Brian Horine
 Greg Hostetler
 Lisa Howell
 Lou Ann Hughes
 Shannan Hunt
 Loan Huynh
 Chris Itteilag
 Meera Iyengar, MD
 Jodeen Jach
 Jami Shields
 Jared Shusterman's
 Campaign Team
 Andrew Jaynes
 JE Dunn Construction
 Jerry Maahs Memorial
 Golf Classic
 Joanna Marker's Man & Woman
 of the Year Campaign
 Jodeen Jach's Man & Woman
 of the Year Campaign

Danielle Johnston
 Jonathan M. Eisenberg &
 We B Stronga
 Megan Jones
 Michelle Jordan-Berndt
 Just Cure It
 Anne Kacmarcik Johnson
 Ari Kahan
 Homaira Karimi
 Katie Plichta & Team Dream
 and Do
 Betsy Katten
 Rebecca Kellum
 Annie Kelly
 Michael King
 Kiven, Kotler, Lieberman, Fox,
 Joffe, Goldschmidt & Kepes
 Dr. Ramesh Kolluru
 Robert Kottler
 Scott J. Kurinsky
 Victoria Landau
 James Lau
 Chris Lee
 Trenton Leffingwell
 Donald Lewis
 David Liotta
 Danny Loental
 Lu Lunatics Powered by Kailie's
 Krew and Bryan Cave
 Matt Mackowiak
 Marion Elementary School
 Joanna Marker
 Craig Marking
 Roshan Marksman
 Mason City School District -
 Mason High School
 Patrick McAndrew
 Michael J. McBride
 Vanessa McDonald
 Erin McFarland
 Joseph McKenna & Team Lily
 John McNeill
 Simon Tipper-McWhorter
 Otilia Melwani
 Dr. Jeffrey Menashe
 Amy Merrill
 Jake Merrill

Susanna Merriman, RN
 George Meza
 Mission Restaurant Supply
 Mission IS-Possible
 Jon Moellenberg
 Janet Montagne
 Alissa Moody
 Kathleen Moore
 Holly Morales
 Patrick M. Moran
 Corina Morga
 Morgan Stanley
 Dr. George Moynihan
 David M. Murphy
 Emily Murray
 Nolana Mymka Daoust
 Drew Nadlang
 Diva Nagula
 NCA Circle of Hope
 Ryan Neuhard
 Matt Newsom
 Nidec Motor Corporation
 William Nielsen
 Patrick Noble
 Lynne O'Brien
 Sean O'Connell
 Dr. Jack O'Neill
 Kevin O'Neill
 Rick Ostroff
 Angie Palomo
 Partners For A Cure
 Alex Pascual
 Shannon Pasternak
 Vipul Patel, MD
 Patrick Daoud's Campaign Team
 Allen Peacock

† National Man & Woman of the Year

* Denotes multi-year commitment

** Denotes National Man Woman
 of the Year All Star Alum

Pharmaceutical Funding Legend

PA Patient Access R Research
 PP Public Policy C Campaign

Donors (continued)

Lisa Pektor
Perfumania, Inc.
Leslie Pierce
Matthew Priddy, MD
Eric A. Pullen
Gayle Coleman Rader
The RALLY Campaign
Rampart High School
Rawn William's Team
Joseph Reigadas
Re-Remission For Ryan
Caroline Rice
Ride For Ron
Riders of the Storm
Shannon Ridley
Dave Roberts
Connie Robins
Tracy Robinson
Sondra Rose
Roswell High School
Cecile Roth
Mara Sabatini
Salesforce
Sharon Saltzman
Angela San Martin
Sarah Chambliss & #Team Cooper
Christina Saunders
Stefanie Sarantopoulos, MD, PhD
Trevor Sava
Alyssa Schaffer
Nancy Scheid
Doug Schenkel
Lisa Schlehuber
Marc Schneider
Sawaya Segalas
Stephanie M. Senn
Anjali Shah
C. Kevin Shannahan
Lauren Sharaby
Sina Sharifan
Jami Shields
Jared Shusterman
Rich Singley
Julie Zimmet Smith
Timothy Smith

Billy Jack Snelson
Natasha Solis
Tony Sorrentino
Scott Stankavage
Jeffrey Stevens
Stonefield Home, Inc.
Michelle Straessle
Stratford School - Fremont Campus
Strikeout Cancer, Team T.O.
Margaret Struble
Sarah Sturgis
Jennifer Swanton
Cornell Sweeney, Jr.
Zac Talmadge
Morgan Tannenbaum, MD
Jill Tanner
Angela Tatum
Team Acacia
Team b. Strong
Team BE - for Bill
Team BE - for Elizete
Team Beat It
Team Believe
Team Blumenfeld & Waterman
Team Bright Side
Team Coco
Team Driscolls
Team Frank
Team Happily Ever After
Team Ivor
Team Jenny
Team Kathy's Kritters
Team Kaitlin
Team LBS
Team LOL
Team Medtronic
Team NARS
Team Norm
Team Paul
Team PwC
Team Rooster
Team Sally
Team SanDisk
Team SDG&E/Sempra
Team SHINE
Team Tom

Joe Tedesco
Team Terminate Cancer
Team United
Terumo BCT
Christine Thayer
Katie Thomason
Brandon Thompson
Dalton Thompson
Jason Thompson
Toni Anita Hull & Hull's Heroes
Gary Trovato
Jessica Tursi
Nahid Usmani, MD
Joe Vermillion
Joe Vicari**
Virtual Nerd Runs for a Cure
Lindsay Vogelman
Waddell & Reed/Ivy Investments
Ryan Wade
Jennifer Walden, MD
Walt Whitman High School
Walter Johnson High School
Gina & Peter Manos, The Warriors
Washington Gas
Watertown Middle School
Daragh Watson
Brian Waterman
Wayne's World
Cary Wells
Andrea Wert
Patty Werthmann
Lauren E. Wessel
Whipp Cancer Wright Out
Noreen White
Amanda Whitelaw
Sarah Wilbur
Rawn Williams
Thomas Williams, Jr.
Leigh Ann Woodall
Michael Woolf
Mark Yoffe, MD
You Gotta Believe
Joshua Zeidner, MD
Logan Zinman

** Denotes National Man & Woman of the Year All Star Alum

Legacy Circle

Legacy Circle honors those who designate LLS as a beneficiary of their will, trust, retirement account or insurance policy, or fund a charitable gift annuity. We list our newest members below along with those whose bequests of \$10,000 or more were received this year.

Peggy Abbott*	Dennis Gerin*	Doris Schmidt*
Charles Anderson*	Becky Godchaux	Gail Secrist*
Thomas Angelo*	Blanche Goldstein*	Bruno and Irma Selmi*
Renza Moscatelli Baker*	Sylvia Greenberg*	Shirley Shanahan*
Frances Barker*	Jack Hill*	Barrie Simonson*
Nicholas Bartlone*	Joel Hoerth*	Barbara Smith*
Norman and Betty Bertiaux*	Sean Horvath	Marie Stephenson*
Bill Beattie Memorial Fund (Alberta)	Josephine Incammissa*	Judith Ann Stimson*
Violet Blakeley*	Patricia Johnson*	Henry Stuyfzand*
Erwin Brandt*	John Kellenyi	Betty Sultan (In Memory of Stanley Sultan)
James Brewster, III	Rosella Kenaston*	William Summers*
John Cahill (In Memory of Dorothy J. Cahill)	Thomas Keys*	Bruce Swartz*
Eric Carlson*	Olga Kingston*	Edna Swartzbeck*
Dawn Carr	Allen Klein*	Michael Thomas (In Memory of Gerald Eugene Thomas)
Megan Clemens	Vivian Kommosser*	Thomas Jay Thompson* (In Memory of Frances Thompson)
Steve and Shannon Clifford (In Memory of Mary Pat Clifford)	Clara Kraut*	Charles Vivacqua*
Emma Connor*	James Labor*	William Wallace*
Helen Cook*	MaryBeth Lanza	Hollyce Deanna Walsh*
Rodger and Lori Coon*	Gerda Carol Lawson*	Peggy Sue Warren*
Nellie Coudare*	Clairenel Loveland*	Jodi Waterman (In Memory of Stephen H. Waterman)
Dolores Darr*	Carol Lutey*	Estella Ruth Watts*
Millard C. Davis*	Laura MacNeill (In Memory of Elizabeth McGovern)	Andrew Wieseneck (In Memory of Arthur Yeckes)
Peggy and Margaret Dupaquier*	Cynthia Magyary*	Florence Williams*
Alison Edwards	Bernard Mann*	Anonymous (4)
Theresa Eichorn*	Ruth Marcus*	
John Eidel*	Lilly Nelson*	
Mark Elansky*	Alfred Netter	
Christina Elliott*	Michael Pavelec	
Seymour Falik (In Memory of Margot Cole)	Leland Prittie*	
Daryl Fallin*	Ronnie Ram	
Anthony Farmer	Edna Raupp*	
Nellie Fishman*	Ted and Lori Reese	
Deborah Fletcher*	Deborah Reynolds*	
Anita Foster*	David and Melody Robinson	
Timothy Frates	Dominic Rossi	
Bella Frutkin*	Robert Ruhe*	
	Robert Schaub	

* Deceased

Independent Auditors' Report

The Board of Directors
The Leukemia & Lymphoma Society, Inc.:

We have audited the accompanying consolidated financial statements of The Leukemia & Lymphoma Society, Inc. (LLS), which comprise the consolidated balance sheet as of June 30, 2016, and the related consolidated statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the organization's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the organization's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of The Leukemia & Lymphoma Society, Inc. as of June 30, 2016, and the changes in its net assets and its cash flows for the year then ended in accordance with U.S. generally accepted accounting principles.

Report on Summarized Comparative Information We have previously audited LLS's consolidated financial statements, and we expressed an unmodified opinion on those audited consolidated financial statements in our report dated October 21, 2015. In our opinion, the summarized comparative information presented herein as of and for the year ended June 30, 2015 is consistent, in all material respects, with the audited consolidated financial statements from which it has been derived.

KPMG LLP

November 2, 2016

Consolidated Balance Sheet

The Leukemia & Lymphoma Society, Inc. / June 30, 2016 (with comparative amounts at June 30, 2015) (In thousands)

	2016	2015
Assets		
Cash and cash equivalents (note 1)	\$ 18,596	52,897
Prepaid expenses and other assets	2,906	6,049
Legacies and contributions receivable, net (note 5)	17,244	8,989
Investments (note 3)	168,293	137,941
Fixed assets, net (note 7)	<u>16,946</u>	<u>14,826</u>
Total assets	<u>\$ 223,985</u>	<u>220,702</u>
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 13,655	16,975
Deferred revenue (note 6)	12,916	17,802
Awards and grants payable (note 2)	60,451	69,335
Co-Pay assistance payable (note 2)	13,469	14,465
Other long-term liabilities (note 1)	<u>1,638</u>	<u>1,441</u>
Total liabilities	<u>102,129</u>	<u>120,018</u>
Commitments and contingencies (notes 2 and 9)		
Net assets (note 4):		
Unrestricted	84,178	72,848
Temporarily restricted	34,241	24,146
Permanently restricted	<u>3,437</u>	<u>3,690</u>
Total net assets	<u>121,856</u>	<u>100,684</u>
Total liabilities and net assets	<u>\$ 223,985</u>	<u>220,702</u>

See accompanying notes to consolidated financial statements.

Consolidated Statement of Activities

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2016 (with summarized totals for the year ended June 30, 2015) (In thousands)

	Unrestricted	Temporarily restricted	Permanently restricted	Total	
				2016	2015
Operating revenue					
Campaign contributions	\$ 235,036	23,279	64	258,839	259,429
Less direct donor benefit costs	(26,348)	—	—	(26,348)	(24,606)
Net campaign contributions	208,688	23,279	64	232,491	234,823
Co-pay contributions	—	46,379	—	46,379	43,000
Legacies	5,159	2,787	—	7,946	10,157
Donated services and media (note 6)	11,175	—	—	11,175	9,864
Net interest and dividend income	1,347	5	—	1,352	1,904
Net assets released from restrictions (note 2):					
Co-pay assistance	44,673	(44,673)	—	—	—
Satisfaction of other donor restrictions	18,102	(18,062)	(40)	—	—
Total operating revenue	289,144	10,175	24	299,343	299,748
Operating expenses (note 6 and 10)					
<i>Program services:</i>					
Research	54,691	—	—	54,691	71,540
Patient and community service	89,209	—	—	89,209	95,526
Public health education	42,881	—	—	42,881	36,249
Professional education	15,373	—	—	15,373	16,829
Total program services	202,154	—	—	202,154	220,144
<i>Supporting services:</i>					
Management and general	27,553	—	—	27,553	31,006
Fund raising	44,749	—	—	44,749	46,205
Total supporting services	72,302	—	—	72,302	77,211
Total operating expenses	274,456	—	—	274,456	297,355
Change in net assets from operating activities	14,688	10,175	24	24,887	2,393
Foreign currency translation adjustment	(30)	(80)	—	(110)	(530)
Net decrease in fair value of investments (note 3)	(4,157)	—	—	(4,157)	(1,585)
Net assets transferred and reclassified (note 1)	829	—	(277)	552	—
Change in net assets	11,330	10,095	(253)	21,172	278
Net Assets					
Beginning of year	72,848	24,146	3,690	100,684	100,406
End of year	\$ 84,178	34,241	3,437	121,856	100,684

See accompanying notes to consolidated financial statements.


Consolidated Statement of Functional Expenses

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2016 (with comparative totals for the year ended June 30, 2015) (In thousands)

	Program Services					Supporting Services			Total		Direct Donor Benefit Costs	
	Research	Patient and community service	Public health education	Professional education	Total	Management and general	Fund raising	Total	2016	2015	2016	2015
	Awards and grants (note 2)	\$ 40,011	—	—	—	40,011	—	—	—	40,011	53,717	—
Therapy acceleration program (note 2)	9,343	—	—	—	9,343	—	—	—	9,343	13,503	—	—
Financial aid to patients	—	1,299	—	—	1,299	—	—	—	1,299	430	—	—
Co-pay assistance (note 2)	—	40,030	—	—	40,030	—	—	—	40,030	41,804	—	—
Co-pay processing fees	—	3,375	—	—	3,375	—	—	—	3,375	4,581	—	—
Donated services and media (note 6)	113	2,754	831	—	3,698	—	7,477	7,477	11,175	9,864	—	—
Salaries	2,714	19,096	18,331	7,243	47,384	12,826	13,888	26,714	74,098	79,199	—	—
Employee benefits and taxes (note 8)	547	4,327	4,161	1,655	10,690	2,760	3,075	5,835	16,525	16,519	—	—
Occupancy (note 9)	76	2,711	2,543	902	6,232	1,285	1,709	2,994	9,226	9,566	—	—
Insurance	55	163	84	27	329	273	52	325	654	665	—	—
Telephone	47	659	459	187	1,352	293	338	631	1,983	2,276	—	—
Travel and meetings	531	1,699	1,791	848	4,869	1,282	1,331	2,613	7,482	7,854	13,672	13,765
Printing, advertising, and supplies	124	3,200	3,858	926	8,108	2,143	6,543	8,686	16,794	17,446	4,715	4,181
Equipment rentals and maintenance	91	1,569	1,159	463	3,282	710	836	1,546	4,828	3,580	—	—
Postage and shipping	39	1,410	2,222	331	4,002	464	2,836	3,300	7,302	7,411	—	—
Professional fees	715	3,953	4,717	1,649	11,034	2,992	4,632	7,624	18,658	20,244	1,687	1,299
Miscellaneous	138	1,293	1,060	460	2,951	1,461	811	2,272	5,223	2,916	6,274	5,361
Depreciation and amortization	147	1,671	1,665	682	4,165	1,064	1,221	2,285	6,450	5,780	—	—
Total expenses	\$ 54,691	89,209	42,881	15,373	202,154	27,553	44,749	72,302	274,456	297,355	26,348	24,606

See accompanying notes to consolidated financial statements.

Total Program Services	73.7%
Total Supporting Services	26.3%
Total Expenses	100.0%



Consolidated Statement of Cash Flows

The Leukemia & Lymphoma Society, Inc. / Year ended June 30, 2016 (with comparative amounts for the year ended June 30, 2015) (In thousands)

	2016	2015
Cash flows from operating activities:		
Change in net assets	\$ 21,172	278
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Net decrease in fair value of investments	4,157	1,585
Depreciation and amortization	6,450	5,780
Provision for uncollectible accounts	(445)	126
Change in long-term liability	197	(425)
Changes in operating assets and liabilities:		
Prepaid expenses and other assets	3,143	(687)
Legacies and contributions receivable	(7,810)	(2)
Accounts payable and accrued expenses	(3,320)	(1,844)
Deferred revenue	(4,886)	(8,943)
Awards and grants payable	(8,884)	(14,866)
Co-Pay assistance payable	(996)	2,233
Net cash provided by (used in) operating activities	<u>8,778</u>	<u>(21,231)</u>
Cash flows from investing activities:		
Purchases of fixed assets	(8,570)	(4,002)
Purchases of investments	(238,736)	(36,640)
Sales of investments	204,227	85,999
Net cash (used in) provided by investing activities	<u>(43,079)</u>	<u>45,357</u>
Net (decrease) increase in cash and cash equivalents	(34,301)	24,126
Cash and cash equivalents at beginning of year	<u>52,897</u>	<u>28,771</u>
Cash and cash equivalents at end of year	<u>\$ 18,596</u>	<u>52,897</u>

See accompanying notes to consolidated financial statements.

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2016

1] Organization and Summary of Significant Accounting Policies

A] Organization

The Leukemia & Lymphoma Society, Inc. (LLS) is the world's largest voluntary health agency dedicated to finding cures for blood cancers. LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease, and myeloma and improve the quality of life of patients and their families. LLS research grants have funded many of today's most promising advances for the treatment of blood cancer patients, including targeted therapies and immunotherapies. LLS is a leading source of publicly available information regarding blood cancer, and education and support programs. LLS influences public policies that accelerate the development and approval of new blood cancer therapies and advocates for all blood cancer patients and their families, helping patients navigate their cancer treatments and access to quality, affordable and coordinated care. LLS is dedicated to removing barriers to care by representing the healthcare and medical research interests of patients and families to policy makers at all levels of government.

B] Principles of Consolidation

The accompanying consolidated financial statements include the accounts of LLS, which encompasses the National Office of LLS and its fifty six chapters in the United States, and LLS's not for profit affiliates, The Leukemia & Lymphoma Society of Canada, Inc. (LLSC) and its five chapters in Canada, The Leukemia & Lymphoma Society Research Programs, Inc. (LLSRP), The Leukemia & Lymphoma Society Research Foundation (LLSRF), Beat AML (BAML) and PearlPoint Cancer Support, Inc. (PPCS). Effective March 28, 2016, LLS became the sole member of PPCS. As part of the assumption of control, LLS recognized a transfer of net assets of approximately \$552,000. All significant intercompany and intra LLS accounts and transactions have been eliminated in consolidation.

C] Tax-Exempt Status

LLS, LLSRP, LLSRF and PPCS qualify as charitable organizations as defined by Internal Revenue Code Section 501(c)(3) and, accordingly, are exempt from federal income taxes under Internal Revenue Code Section 501(a). Additionally, since these organizations are publicly supported, contributions qualify for the maximum charitable contribution deduction under the Internal Revenue Code.

LLSC is registered as a charitable organization under the Income Tax Act (Canada) and is, therefore, not subject to income taxes if certain disbursement requirements are met.

BAML is a single member limited liability company and is a disregarded pass-through entity. Accordingly, all revenue and expenses are included in LLS. Income of BAML is exempt from federal income taxes under Internal Revenue Code Section 501(c)(3) consistent with LLS.

LLS and PPCS recognize the effect of income tax positions only if those tax positions are more likely than not to be sustained. Income generated from activities unrelated to exempt purposes are subject to tax under Internal Revenue Code Section 511. There were no entities that recognized any unrelated business income tax liability for the years ended June 30, 2016 and 2015.

D] Estimates

The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires LLS's management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The significant estimates made in the preparation of these consolidated financial statements include the fair value of alternative investments, allowance for uncollectible accounts, allocation of expenses, and valuation of donated services and media. Actual results could differ from those estimates.

E] Risks and Uncertainties

LLS invests in various investment securities. Investment securities are exposed to various risks such as interest rate risks, fluctuations in market values, and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the consolidated balance sheet.

LLS's principal source of revenue is contributions by the general public. Accordingly, LLS's operations are dependent upon individual contributions, that are affected by general economic conditions, employment levels, and other factors over which LLS has little or no control. By contrast to the granularity of the general public donations, the co-pay program in 2016 and 2015 was funded by nine and eight donors, respectively.

F] Summarized Financial Information

The consolidated financial statements are presented with 2015 summarized or comparative information. With respect to the consolidated statement of activities, such prior year information is not presented by net asset class and, in the consolidated statement of functional expenses, 2015 expenses by object are presented in total rather than by functional category. Accordingly, such information should be read in conjunction with LLS's 2015 consolidated financial statements from which the summarized information was derived.

G] Subsequent Events

LLS evaluated subsequent events after the balance sheet date of June 30, 2016 through November 2, 2016, which was the date the consolidated financial statements were issued.

On August 23, 2016, LLS received a payment triggered by a change in control clause within a Therapy Acceleration Program (TAP) agreement. LLS funded several phases of research and clinical trials as part of this agreement. In addition to the payment received, LLS may receive additional payments contingent on the advancement of drug FDA approval and commercialization.

H] Net Asset Classifications

To ensure observance of limitations and restrictions placed on the use of resources available to LLS, funds that have similar characteristics have been classified into three net asset categories as follows:

Unrestricted net assets: Consist of funds that are fully available, at the discretion of LLS's Board of Directors, for LLS to utilize in any of its programs or supporting services.

Temporarily restricted net assets: Consist of funds that are restricted by donors for a specific time period and/or purpose.

Permanently restricted net assets: Consist of funds that contain donor imposed restrictions requiring that the principal be invested in perpetuity. Income earned on these funds is recorded as temporarily restricted net assets and is released from restriction when the donor stipulated purpose has been fulfilled and/or the amount has been appropriated in compliance with the Board approved spending policy (note 4).

I] Foreign Currency Translation

LLSC uses the Canadian dollar as its functional currency. Accordingly, the currency translation of the financial statements of LLSC to U.S. dollars is included as a translation adjustment in the consolidated statement of activities.

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2016

J] Fair Value Measurements

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- Level 2 inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 unobservable inputs for the asset or liability.

LLS follows the provisions of Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, for its alternative investments that do not have readily determinable fair values, including hedge funds, limited partnerships, and other funds. This guidance allows, as a practical expedient, for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value, using net asset value per share or its equivalent, as reported by the investment managers.

The classification of investments in the fair value hierarchy is not necessarily an indication of the risks, liquidity, or degree of difficulty in estimating the fair value of each investment's underlying assets and liabilities.

K] Contributions, Grants and Deferred Revenue

Contributions are recorded as revenue, at their fair value, when received or promised unconditionally. Contributions received with donor restrictions that limit their use are reported as either temporarily or permanently restricted revenue. When a donor restriction is met through the passage of time or fulfillment of a purpose restriction, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the consolidated statement of activities as net assets released from restrictions. Conditional contributions are recognized as revenue when the conditions have been substantially met. Certain grants are accounted for as exchange transactions whereby revenue is recognized when the related expenses are incurred. Amounts received under these arrangements but not yet expended are reported as deferred revenue.

L] Donated Services

LLS has determined that certain of the donated services it receives meet the criteria for recognition in the consolidated financial statements. The value of contributed services was determined for volunteers that possess specialized skills, and would otherwise need to be purchased. These services are recognized as revenue and expense (note 6).

M] Donated Media

LLS has conducted national public service announcements (PSA) media campaigns and benefited from donated media time that was aired on television and radio. The value of contributed media, which is recognized in the consolidated financial statements, was estimated based on the placement, audience, and demographics of the PSA's (note 6).

N] Cash Equivalents

Cash equivalents consist of short term investments with an original maturity of three months or less from date of purchase, except for amounts held in investments.

O] Investments

Investments are stated at fair value based upon quoted market prices, except for the fair values of alternative investments which are based on net asset values provided by the fund managers or general partners, based upon the underlying net assets of the funds consistent with the concepts of ASC 820. These values are reviewed and evaluated by management.

P] Fixed Assets and Depreciation

Fixed assets, which consist principally of equipment, software, and leasehold improvements, are recorded at cost, and are depreciated or amortized using the straight-line method over the estimated useful lives of the assets or the terms of the leases, if shorter, ranging 2 to 10 years (leasehold improvements 7 years; furniture, fixtures, and office equipment 7 to 10 years, and computer equipment and software 2 to 5 years).

Q] Other Long-Term Liabilities

Other long-term liabilities represent LLS's liability for the Internal Revenue Code Section 457 deferred compensation plans recorded at fair market value (note 8) and straight-line rent of office leases (note 9).

R] Professional Fees

Professional fees included in the consolidated financial statements principally include professional fund-raising fees, contracted software development, and legal and auditing fees.

S] Reclassifications

Certain reclassifications of 2015 amounts have been made to conform to the 2016 presentation.

2] Research and Co-Pay Assistance Program

LLS has various activities that are utilized to carry out its mission as presented below:

Research

Awards and Grants: Awards and grants for research are approved by LLS's Board of Directors and are recognized as expense when contractual conditions have been satisfied. The budgets for multi year grants, which are generally two to five years in length, are approved on an annual basis and may be terminated at the discretion of LLS's Board of Directors. LLS has multi year grant commitments of \$56,541,000 at June 30, 2016, which are conditioned upon future events and, accordingly, are not recorded. LLS has unconditional grants payable of \$60,451,000 and \$69,335,000 at June 30, 2016 and 2015, respectively, which are anticipated to be paid in the next year. Grant refunds of approximately \$450,000 and \$3,104,000 as of June 30, 2016 and 2015, respectively, have been netted against awards and grants expense.

TAP is LLS's strategic initiative to speed the development of blood cancer treatments and supportive diagnostics by creating business alliances with biotechnology and pharmaceutical companies. TAP provides funding for investigational new drug enabling studies and clinical stage projects. TAP contracts are recognized as an expense in the year program milestones are achieved. Multi-year contracts, which are generally two to three years in length, are reviewed against milestones on a quarterly basis and may be terminated at the discretion of LLS's Board of Directors. LLS has contract commitments of \$10,214,000 and \$20,842,000 at June 30, 2016 and 2015, respectively, that are conditioned upon future events and, accordingly, are not recorded.

Commitments for the awards and grants and TAP programs are contingent upon the satisfactory completion of milestones and/or other conditions in the grant and contract agreements. If such conditions are satisfied, the amounts are estimated to be paid as follows (in thousands):

Year ending June 30:

2017	\$ 34,812
2018	17,298
2019 and thereafter	14,645
Total	<u>\$ 66,755</u>

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2016

Co-Pay Assistance Program

Co-Pay Assistance Program: The Co Pay Assistance program offers financial assistance to patients in meeting their insurance co pay obligations for prescription medications or private/public health insurance premiums. Amounts awarded under the program are expensed in the year approved based on the available funding in the program. Revenue is recognized when the grants are received while expenses are recognized as patients are approved for participation according to program criteria. Accordingly, LLS has recognized \$8,960,000 and \$7,254,000 in temporarily restricted revenue as of June 30, 2016 and 2015, respectively, for which the corresponding expense is not recognized until the subsequent fiscal year as patients are approved in the program. The Co-Pay Assistance payable of \$13,469,000 and \$14,465,000 has been established based on approved patient applications received through June 30, 2016 and 2015, respectively. At June 30, 2016, temporarily restricted net assets include \$8,960,000 received in 2016, which are available for expenditure and are intended to be awarded in fiscal 2017.

The following summarizes the activities of the Co-Pay Assistance program in 2016 and 2015 (in thousands).

	2016	2015
Beginning balance	\$ 7,254	11,707
Grant commitments	46,379	43,000
Amount expended during the year:		
Direct assistance to patients	(40,030)	(41,804)
Other expenses incurred and reimbursed under the contract	(4,643)	(5,649)
Amounts available for expenditures in the next year	<u>\$ 8,960</u>	<u>7,254</u>

3] Investments

The following tables present LLS's fair value hierarchy of investments measured at fair value on an annual basis as of June 30, 2016 and 2015 (in thousands):

	2016	Level 1	Level 2	Level 3
Money market funds and cash	\$ 58,704	58,704	-	-
Fixed income:				
Corporate bonds	36,228	36,228	-	-
Government securities and other	2,032	2,032	-	-
Equities:				
Large cap equity	22,466	22,466	-	-
International equity	20,406	20,406	-	-
Small/mid cap equity	10,429	10,429	-	-
Real estate	5,293	5,293	-	-
Commodities	2,996	2,996	-	-
	<u>\$158,554</u>	<u>158,554</u>	<u>-</u>	<u>-</u>
Investments reported at net asset value:	7,503			
Multistrategy hedge funds	<u>2,236</u>			
Long/short equities	<u>9,739</u>			
Total investments reported at net asset value	<u>\$168,293</u>			

	2015	Level 1	Level 2	Level 3
Money market funds and cash	\$ 18,544	18,544	-	-
Fixed income:				
Long duration fixed income (mutual fund)	27,599	27,599	-	-
Short duration fixed income (mutual fund)	30,222	30,222	-	-
Government securities and other	2,285	2,285	-	-
Equities:				
Large cap equity	7,577	7,577	-	-
International equity	5,355	5,355	-	-
Small/mid cap equity	223	223	-	-
Real assets	<u>5,638</u>	<u>5,638</u>	<u>-</u>	<u>-</u>
	<u>\$ 97,443</u>	<u>97,443</u>	<u>-</u>	<u>-</u>
Investments reported at net asset value:				
Multistrategy hedge funds	38,075			
Long/short equities	<u>2,423</u>			
Total investments reported at net asset value	<u>40,498</u>			
	<u>\$137,941</u>			

In 2016, LLS transitioned from a traditional Investment custodian to an Outsourced Chief Investment Officer. In this process, LLS liquidated its investment portfolio and re-invested all funds.

Investment expenses of \$560,000 and \$866,000 have been netted against the net decrease in fair value of investments for the years ended June 30, 2016 and 2015, respectively. The unrealized gains (losses) were \$3,513,000 and (\$4,851,000) for the years ended June 30, 2016 and 2015, respectively.

LLS's alternative investments are diversified across two investment strategies, as follows:

1. *Multi strategy hedge funds* – represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies and include event driven strategies, distressed debt, merger and other arbitrage, and value investing.
2. *Long/short equities* – primarily investments in funds that, in turn, invest in liquid, marketable securities, attempting to realize gains through the identification of mispriced securities.

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2016

These strategies create indirect exposure to LLS through short sales of securities, trading in future and forward contracts, and other derivative products. Derivatives are investment contracts used to hedge risk. While these financial instruments may contain varying degrees of risk, LLS's risk with respect to such transactions is limited to its capital balance in each investment.

LLS's alternative investments contain various redemption restrictions with required written notice ranging from 45-95 days. By contrast, all of LLS's nonalternative investments are highly liquid and can be redeemed daily without restriction. As of June 30, 2016 and 2015, the following table summarizes the redemption provisions for those investments reported at net asset value (in thousands):

Redemption period	2016	2015
Quarterly	\$ 6,003	38,075
Annual	3,736	2,423
Total	<u>\$ 9,739</u>	<u>40,498</u>

In accordance with ASU 2015 10, *Technical Corrections and Improvements*, LLS removed \$6,965,000 as of June 30, 2015 from investments reported at net asset value (or its equivalent) and included these amounts in Level 1 to correct the fair value hierarchy table.

As of June 30, 2016 and 2015, LLS has no unfunded commitments on its alternative investments.

4] Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets and the income earned on permanently restricted net assets are available for the following purposes at June 30, 2016 and 2015 (in thousands):

	2016		2015	
	Temporarily restricted	Permanently restricted	Temporarily restricted	Permanently restricted
Time restrictions	\$ 272	–	\$ 607	–
Research	19,377	3,280	11,738	3,543
Patient service	5,367	–	4,432	–
Co-pay assistance	8,960	–	7,254	–
Other	265	157	115	147
Total	<u>\$ 34,241</u>	<u>3,437</u>	<u>\$ 24,146</u>	<u>3,690</u>

LLS follows the provisions of the New York Prudent Management of Institutional Funds Act (NYPMIFA), which imposes guidelines on the management and investment of endowment funds. LLS has interpreted the relevant law as allowing LLS to appropriate for expenditure or accumulate so much of an endowment fund as LLS determines is prudent considering the uses, benefits, purposes, and duration for which the endowment fund is established, subject to the intent of the donor as expressed in the gift instrument.

LLS has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to protect the original value of the gift. The spending rate policy at June 30, 2016 and 2015 was 4%, plus any additional amounts advised by donors. Under this policy, the endowment assets are invested in a manner that is intended to produce results consistent with LLS's overall investment strategy.

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2016 (in thousands):

	Temporarily restricted	Permanently restricted	Total
Endowment net assets at July 1	\$ 3,086	3,690	6,776
Investment (loss) income	(164)	64	(100)
Net appreciation	280	–	280
Reclassifications	–	(277)	(277)
Appropriation for expenditure	(240)	(40)	(280)
Endowment net assets at June 30	<u>\$ 2,962</u>	<u>3,437</u>	<u>6,399</u>

The following table presents changes in the donor restricted endowment funds for the year ended June 30, 2015 (in thousands):

	Temporarily restricted	Permanently restricted	Total
Endowment net assets at July 1	\$ 3,164	3,575	6,739
Investment income	61	43	104
Net appreciation	82	72	154
Appropriation for expenditure	(221)	–	(221)
Endowment net assets at June 30	<u>\$ 3,086</u>	<u>3,690</u>	<u>6,776</u>

5] Legacies and Contributions Receivable

LLS's legacies and contributions receivable at June 30, 2016 and 2015 consist of unconditional promises to give and legacies for which the underlying wills have been declared valid by the probate court and no other conditions are required to be met. Contributions receivables are originally recorded based on discounted cash flows using a risk adjusted discount rate. Amounts are scheduled to be received as follows (in thousands):

	2016	2015
Less than one year	\$ 10,723	7,111
1 to 5 years	7,272	2,413
After 5 years	50	575
Subtotal	18,045	10,099
Less:		
Allowance for uncollectible accounts	(169)	(614)
Discount to present value (1.5% to 5.0%)	(632)	(496)
Total	<u>\$ 17,244</u>	<u>8,989</u>

As of June 30, 2016, 65% of gross legacies and contributions receivable were from two funding sources.

Notes to Consolidated Financial Statements

The Leukemia & Lymphoma Society, Inc. / June 30, 2016

6] Deferred Revenue, Donated Services and Media

During 2013, LLS received a \$20,000,000 grant with the contractual agreement to be utilized for research that is jointly identified by the grantor and LLS. At June 30, 2016 and 2015, the unexpended balances of the grant of \$1,145,000 and \$4,504,000, respectively, are included in deferred revenue. Revenue under this grant is expected to be recognized over the next year, as expenses are incurred. The remaining balance of deferred revenue includes amounts received for special events that will be held subsequent to the fiscal year end.

The value of donated services for family support group facilitators and research grant reviewers, as well as donated media are included in both revenue and expense as shown below (in thousands):

	2016	2015
Donated services	\$ 2,867	4,468
Donated media	8,308	5,396
Total	<u>\$ 11,175</u>	<u>9,864</u>

7] Fixed Assets, Net

Fixed assets at June 30, 2016 and 2015 consist of the following (in thousands):

	2016	2015
Leasehold improvements	\$ 1,434	1,109
Furniture, fixtures, and other office equipment	3,397	2,629
Computer equipment and software	39,706	31,829
Total	\$ 44,537	35,567
Less accumulated depreciation and amortization	(27,591)	(20,741)
Fixed assets, net	<u>\$ 16,946</u>	<u>14,826</u>

8] Retirement Plans

LLS has a defined contribution 403(b) plan covering all employees meeting age and service requirements. LLS contributions are based on a percentage of each eligible employee's salary and years of service. Expenses under this plan aggregated \$1,827,000 and \$1,858,000 for the years ended June 30, 2016 and 2015, respectively.

LLS has nonqualified deferred compensation plans for its executive staff subject to the provisions of the Internal Revenue Code Section 457 (the 457 Plans). Expenses under the 457 Plans approximated \$10,000 for the year ended June 30, 2015. There were no expenses incurred for the year ended June 30, 2016. The assets of the 457 Plans are included in investments in the accompanying consolidated balance sheet and amounted to approximately \$1,405,000 and \$1,490,000 at June 30, 2016 and 2015, respectively. The liabilities of the 457 Plans are included in other long term liabilities in the accompanying consolidated balance sheet and amounted to approximately \$1,374,000 and \$1,380,000 at June 30, 2016 and 2015, respectively.

9] Lease Commitments

The leases for premises, which LLS's National Office and chapters occupy, expire on various dates through March 31, 2031, and provide for certain payments subject to escalation and periodic rate increases relating to real estate taxes, operating expenses, and utilities. On September 15, 2015, LLS entered into a 15 year lease for 41,868 square feet of space for its National Office beginning March 2016. The lease terms provide for one year of rent abatement. Free rent periods, tenant improvement allowances, and charges are accounted for on a straight-line basis over the life of the lease.

The approximate minimum aggregate future annual rental commitments are summarized as follows (in thousands):

Year ending June 30:	
2017	\$ 6,008
2018	5,584
2019	4,560
2020	4,071
2021	3,670
Thereafter	15,286
Total	<u>\$ 39,179</u>

10] Joint Costs Allocation

For the years ended June 30, 2016 and 2015, LLS incurred expenses to conduct activities that had both fundraising appeals as well as mission program and management and general components (joint activities). Those joint activities included direct mail, coinboards, and media campaigns. Such costs are allocated based on applicable accounting standards and were allocated as follows (in thousands):

	2016	2015
Fund raising	\$ 13,901	15,294
Patient and community service	2,076	1,152
Public health education	5,117	3,179
Total	<u>\$ 21,094</u>	<u>19,625</u>

National Leaders

Chairman of the Board
James H. Davis, PhD, JD
Palm Beach Gardens, FL

Vice Chair
Elizabeth J. (Betsy) Clark
ACSW
Saugerties, NY

Secretary/Treasurer
Kenneth M. Schwartz
EY
New York, NY

At Large
Donald R. Proctor
Cisco Systems
San Jose, CA

Board of Directors

James A. Beck
Hefren-Tillotson, Inc.
Butler, PA

William G. Behnke
The Behnke Group
San Antonio, TX

Jorge L. Benitez
CEO Accenture NA, retired
Coral Gables, FL

Peter Bennett Brock
Brock Development Corp.
Palm Beach Gardens, FL

A. Dana Callow, Jr.
Boston Millennia Partners
Boston, MA

Scott A. Carroll, JD
Jackson Lewis
Cincinnati, OH

William S. Dalton, MD, PhD
M2Gen
Tampa, FL

Graciela C. Eleta
Eleta Consulting, Inc.
Guaynabo, PR

Bernard H. Garil
Delray Beach, FL

Francie Heller
Heller Advisory
New York, NY

Raanan Horowitz
Elbit Systems of America, LLC
Fort Worth, TX

Richard M. Jeanneret
EY
New York, NY

Joseph B. Kelley
Lilly USA, LLC
Washington, DC

Ralph E. Lawson
Baptist Health South Florida
Coral Gables, FL

Michelle LeBeau, PhD
University of Chicago
Chicago, IL

Gilles B. Legault
Global Legal Affairs
Montréal, Quebec, Canada

Connie L. Lindsey
Northern Trust
Chicago, IL

Steven T. Rosen, MD, FACP
City of Hope
Duarte, CA

Bart Sichel
Burlington Stores
Florence Township, NJ

Frank O. Smith, III, MD
Medpace
Cincinnati, OH

Kathryn C. Vecellio
Vecellio Group
Palm Beach, FL

Louise G. Warner
Chagrin Falls, OH

Keith S. White
ParkerWhite Brand Interactive
Cardiff by the Sea, CA

Executive Leadership

The Leukemia & Lymphoma Society

Louis J. DeGennaro, PhD
President & CEO

Danielle Gee
Chief of Staff

Andrew S. Coccari, Jr.
Executive Vice President
Chief Product Officer

Rosemarie Loffredo
Executive Vice President
Chief Financial & Administrative Officer

Alice O'Rourke
Executive Vice President
Chief Development Officer

Mark Roithmayr
Executive Vice President
Chief Relationship Officer

The Leukemia & Lymphoma Society of Canada

Shelagh Tippet-Fagyas
President
Canadian Operations

Offices

Alabama

Alabama / Gulf Coast
3500 Blue Lake Drive • Suite 225
Birmingham, AL 35244
205.989.0098

Alaska

See Washington

Arizona

3877 North 7th Street • Suite 300
Phoenix, AZ 85014
602.567.7600

Arkansas

See Missouri

California

California Southland
4929 Wilshire Boulevard • Suite 800
Los Angeles, CA 90010
310.342.5800

Central California
340 West Fallbrook Avenue
Suite 101

Fresno, CA 93711
559.435.1482

Greater Bay Area / San Francisco
221 Main Street • Suite 1650
San Francisco, CA 94105
415.625.1100

Orange County / Inland Empire
515 North Cabrillo Park Drive
Suite 102

Santa Ana, CA 92701
714.481.5600

Sacramento
7750 College Town Drive • Suite 210
Sacramento, CA 95826
916.929.4720

San Diego / Hawaii
9150 Chesapeake Drive • Suite 100
San Diego, CA 92123
858.427.6648

Silicon Valley / Monterey Bay
675 North First Street • Suite 1100
San Jose, CA 95112-5156
408.490.2666

Colorado

Rocky Mountain
720 South Colorado Boulevard
Suite 500-S
Denver, CO 80246
720.440.8620

Connecticut

Connecticut / Westchester
Hudson Valley / CTWHV
3 Landmark Square • Suite 330
Stamford, CT 06901
203.388.9160

Delaware

100 West 10th Street • Suite 209
Wilmington, DE 19801
302.661.7300

Florida

North & Central Florida
341 Maitland Avenue • Suite 101
Maitland, FL 32751
407.898.0733

40 E Adams Street • Suite LL40
Jacksonville, FL 32202
904.332.6414

Palm Beach Area
3230 Commerce Place • Suite B204
West Palm Beach, FL 33407
561.616.8682

Southern Florida & Puerto Rico
200 South Park Road • Suite 140
Hollywood, FL 33012
954.744.5300

Suncoast
3507 East Frontage Road • Suite 300
Tampa, FL 33607
813.963.6461

Georgia

3715 Northside Parkway
Building 400 Northcreek • Suite 300
Atlanta, GA 30327
404.720.7900

Hawaii

PMB 222
111 Hekili Street • Suite A
Kailua, HI 96734

Illinois

954 West Washington Boulevard
Suite 300
Chicago, IL 60607
312.651.7350

Indiana

9075 North Meridian Street
Suite 150
Indianapolis, IN 46260
317.860.3840

Iowa

Century 1 Building
2700 Westown Parkway • Suite 260
West Des Moines, IA 50266
515.270.6169

Kansas

Mid-America
6811 Shawnee Mission Parkway
Cloverleaf Building #1 • Suite 202
Shawnee Mission, KS 66202-4001
913.262.1515

Kentucky / Southern Indiana

301 East Main Street • Suite 100
Louisville, KY 40202-1077
502.584.8490

Lexington Office

836 Euclid Avenue • Suite 317
Lexington, KY 40502
859-226-0764

Maine

See Massachusetts

Maryland

100 Painters Mill Road • Suite 800
Owings Mills, MD 21117
443.471.1600

Massachusetts

9 Erie Drive
Natick, MA 01760
508.810.1300

Michigan

1471 East Twelve Mile Road
Building H
Madison Heights, MI 48071
248.581.3900

Minnesota

1711 Broadway Street NE
Minneapolis, MN 55413
612.259.4600

Mississippi / Louisiana

3636 South 1-10 Service Road
Suite 304
Metairie, LA 70001
504.837.0945

Missouri

Gateway
1972 Innerbelt Business Center Drive
St. Louis, MO 63114
314.590.2230

Montana

See Oregon

Nebraska

12100 West Center Road
Building 1 • Suite 202
Omaha, NE 68144
402.344.2242

Nevada

Southern Nevada
6280 South Valley View Boulevard
Suite 342
Las Vegas, NV 89118
702.436.4220

New Hampshire

See Massachusetts

New Jersey

14 Commerce Drive • Suite 301
Cranford, NJ 07016
908.956.6600

New Mexico / El Paso

6100 Indian School Road NE
Suite 225
Albuquerque, NM 87110
505.872.0141

New York / Vermont

Long Island
3 Huntington Quadrangle Suite 202S
Melville, NY 11747
631.370.7530

New York City
61 Broadway • Suite 400
New York, NY 10006
212.376.7100

Upstate New York / Vermont

5 Computer Drive West • Suite 100
Albany, NY 12205
518.438.3583

Western & Central New York
4043 Maple Road • Suite 105
Amherst, NY 14226
716.834.2578

North Carolina

401 Harrison Oaks Boulevard
Suite 200
Cary, NC 27513
919.367.4100

North Dakota

See Minnesota

Ohio

Central Ohio
2215 Citygate Drive • Suite A
Columbus, OH 43219
614.476.7194

Northern Ohio

5700 Brecksville Road • 3rd Floor
Independence, OH 44131
216.264.5680

Tri-State / Southern Ohio
4370 Glendale-Milford Road
Cincinnati, OH 45242
513.698.2828

Oklahoma

500 North Broadway • Suite 250
Oklahoma City, OK 73102
405.943.8888

Oregon / Southern Washington / Idaho / Montana (OSWIM)

9320 SW Barbur Boulevard
Suite 350
Portland, OR 97219
971.230.2192

Pennsylvania

Central Pennsylvania
2405 Park Drive • Suite 100
Harrisburg, PA 17110
717.652.6520

Eastern Pennsylvania
100 North 20th Street • 4th Floor
Philadelphia, PA 19103
610.238.0360

Western Pennsylvania / West Virginia
333 East Carson Street • Suite 441
Pittsburgh, PA 15219
412.395.2873

Rhode Island

2348 Post Road • Suite 202
Warwick, RI 02886
401.943.8888

South Carolina

107 Westpark Boulevard • Suite 150
Columbia, SC 29210
803.731.4060

South Dakota

See Minnesota

Tennessee

404 BNA Drive • Suite 102
Nashville, TN 37217
615.331.2980

Texas

North Texas
8111 LBJ Freeway • Suite 425
Dallas, TX 75251
972.996.5900

South Central Texas
1218 Arion Parkway • Suite 102
San Antonio, TX 78216
210.998.5400

Texas Gulf Coast
5433 Westheimer Road • Suite 300
Houston, TX 77056
713.840.0483

Utah

5296 Commerce Drive • Suite 101
Murray, UT 84107
801.281.6618

Vermont

See Albany, NY

Virginia

5540 Falmouth Street • Suite 101
Richmond, VA 23230
804.673.5690

Washington / Alaska

123 NW 36th Street • Suite 100
Seattle, WA 98107
206.628.0777

Washington D.C.

National Capital Area
3601 Eisenhower Avenue • Suite 450
Alexandria, VA 22304
703.399.2900

West Virginia

See Pittsburgh, PA

Wisconsin

200 South Executive Drive
Suite 203
Brookfield, WI 53005
262.790.4701

Wyoming

See Colorado

Puerto Rico

P.O. Box 9138
San Juan, PR 00908
787.725.2200

Canada

Canada Home Office
804-2 Lansing Square • Suite 804
Toronto, ON M2J 4P8
416.661.9541 x104

Atlantic Canada Region / Halifax
1660 Hollis Street • HS2
Halifax, NS B3J 1V7
902.422.5999

BC / Yukon Region / Vancouver
303-1401 West Broadway
Vancouver, BC V6H 1H6
604.733.2873

Ontario Region / Toronto
804-2 Lansing Square
Toronto, ON M2J 4P8
647.253.5530

Prairies Region / Calgary
316, 1212 31 Avenue NE
Calgary, AB T2E 7S8
403.263.5300

Région de Québec / Montréal
602-740, rue St-Maurice
Montréal, QC H3C 1L5
514.875.1000

www.ils.org



LEUKEMIA &
LYMPHOMA
SOCIETY®

fighting blood cancers

**someday
is today®**

mission

**cure leukemia, lymphoma, hodgkin's disease and myeloma,
and improve the quality of life of patients and their families.**